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Abstract 
 
THE IMPACT OF CHEMOTHERAPY AND RADIOTHERAPY FOR BREAST CANCER 
ON COGNITION AND FUNCTIONAL PERFORMANCE: A COMPARATIVE ANALYSIS 
OF SURVEY DATA TAKEN AT THREE TIME POINTS POST-TREATMENT 
By Ann Marie Potter, Ph.D. 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University 
Virginia Commonwealth University, 2017 
Dissertation Chair: Tony Gentry, Ph.D. OTR/L, FAOTA,  
Associate Professor, Occupational Therapy Department 
 
Cognitive impairment related to treatment for breast cancer, affects as many as 
75% of patients in study samples (Jansen, Cooper, Dodd & Miaskowski, 2011). Deficits 
in the cognitive domains of short-term memory, attention, speed of information 
processing, judgment, reasoning, spatial attention, and verbal memory have been 
documented. The extent to which these deficits impact functional performance within 
this population has not yet been quantified. The purpose of this study was to investigate 
the impact of breast cancer on self-reported cognition and functional performance in the 
six months post-completion in two groups of breast cancer survivors, a chemotherapy 
group and chemotherapy and radiotherapy group. Cognition and functional performance 
were measured with the Patient Reported Outcomes Measurement Information System 
(PROMIS®). Cognition was measured in terms of abilities and concerns. Functional 
performance measures addressed the constructs of physical function, ability to 
  
participate in social roles and activities, and satisfaction with participation in social roles 
and activities.  
Sixteen female participants (ages 28-45) completed online surveys three weeks 
following the conclusion of chemotherapy or radiotherapy and three and six months 
later. Linear mixed-effects models were used to analyze changes over time within 
groups and compare differences between groups. Over the six months post-treatment 
the chemotherapy group had a significant improvement in physical function (p=.0178), 
and the chemotherapy + radiotherapy group showed significant gains in the ability to 
participate in social roles and activities (p=.0447). Fatigue was a significant factor in the 
chemotherapy + radiotherapy group (p=.015). No significant differences between 
groups were noted for changes in cognition, functional performance or psychosocial 
factors.  
This research provides insight into self-reported changes in cognition and 
functional performance in the six months following breast cancer treatment. Cognition 
and functional performance appear to be interrelated and impacted by a constellation of 
factors that occupational therapists and oncology providers need to be aware of in order 
to best support cancer survivors in the resumption of occupations after treatment. A 
comprehensive approach to assessment and intervention that considers the complexity 
of cognitive performance as it relates to physical capacity and concurrent symptoms is 
recommended.  
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Chapter 1: Introduction 
 
This chapter summarizes current research on the impact of chemotherapy and 
radiotherapy on cognition and functional performance among patients with breast 
cancer. An overview of the problem of post breast cancer cognitive impairment is 
provided, followed by the purpose and specific aims for this study. The chapter 
concludes with discussion of the study rationale and a brief introduction to the 
theoretical underpinnings for this work. 
Post Breast Cancer Cognitive Impairment 
The relative survival rate for all stages of breast cancer in the United States is 
89.5% (Howlander, et al. 2015). In response, clinicians are expanding care to include 
recovery and survivorship, including attention to symptoms and sequelae related to 
cancer treatment (Alfano, Ganz, Rowland & Hahn, 2012). Cognitive problems 
associated with breast cancer treatment are a major concern for survivors. The 
“impairment of patients’ memory, learning, concentration, reasoning, executive function, 
attention, and visuospatial skills during and after the discontinuation of chemotherapy” is 
commonly referred to as chemobrain or chemofog (Argyriou, Assimakopoulos, 
Iconomou, Giannakopoulou & Kalafonos, 2011, p. 127). Chemotherapy induced 
cognitive impairment (CICI) and chemotherapy-related cognitive impairment (CRCI) are 
terms frequently used in the literature (Jansen, Cooper, Dodd & Miaskowski, 2011; 
Myers, 2009). This terminology originated from early assumptions that chemotherapy is 
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the cause of treatment-related cognitive impairment. Research has demonstrated that a 
variety of factors contribute to cognitive impairment, therefore I am using the term post 
breast cancer cognitive impairment (PBCCI) to better capture the essence of the 
phenomenon as it is now understood. 
The impact of cognitive impairment on the resumption of life activities following 
cancer treatment is not well quantified or understood. Current research into PBCCI 
relies heavily on standardized batteries of neuropsychological tests and self-report 
measures. Standardized neuropsychological testing methods often fail to adequately 
address the impact of cognitive impairment on functional performance (Baddeley, 2004; 
Sbordone, 1996; Wilson, 2004). Functional performance encompasses the ability to 
perform activities of daily living (ADL’s), instrumental activities of daily living (IADL’s) 
and social participation. Self-reports of PBCCI frequently describe decreased 
functioning in these areas that neuropsychological testing fails to uncover (Nelson & 
Suls, 2013).  
The National Comprehensive Cancer Network’s (NCCN) guidelines for 
addressing cancer-related cognitive function recommend occupational therapy as a 
“first line” intervention to assist individuals experiencing specific functional limitations 
related to cognitive impairments associated with any type of cancer diagnosis and 
treatment (Denlinger et al., 2014). Occupational therapists are concerned with the 
impact of impairment on functional performance and how participation in personally 
meaningful activities can be improved. The extent to which cognitive impairment post-
treatment for breast cancer impairs functional performance is not well documented. This 
study utilized the Patient Reported Outcomes Measurement Information System 
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(PROMIS®) to gain a better understanding of any relationship between self-reported 
cognitive abilities and cognitive concerns with functional performance experienced by 
breast cancer survivors who have undergone adjuvant chemotherapy as compared to 
those who have undergone both chemotherapy and radiotherapy.  
Breast Cancer 
Breast cancer is the most commonly diagnosed cancer among American women 
and the second leading cause of cancer death. The National Cancer Institute predicted 
approximately 252,710 new breast cancer diagnoses for 2017 (Howlander, et al. 2017). 
Men account for 1% of breast cancer cases (Howlander, et al. 2015). There are several 
different types of breast cancer: Ductal carcinoma in situ (DCIS), invasive ductal 
carcinoma (IDC), lobular carcinoma in situ (LCIS), invasive lobular carcinoma (ILC) and 
inflammatory breast cancer (IBC). Ductal carcinoma is the most common type of breast 
cancer and begins when the linings of the milk ducts transform into abnormal cancer 
cells. Lobular carcinoma begins in the lobes of the breast. In situ means the cancer is 
enclosed in either the duct or lobe and has not spread to surrounding tissue. Invasive 
cancer has spread into other parts of the breast tissue and possibly beyond to other 
tissues in the body. Inflammatory breast cancer is a rare and aggressive form that is 
caused by cancer cells blocking the lymph vessels in the skin (National Cancer Institute, 
2012).  
Breast cancer is staged according to the TNM classification system: (T) the size 
of the primary tumor, (N) the number of regional lymph nodes where the cancer has 
spread, and (M) distant spread or metastasis (NCI, 2015). DCIS and LCIS are stage 0. 
Stages I-IV are summarized in Table 1.  
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Table 1 
Breast Cancer Staging According to the National Cancer Institute 
Stage TNM Description 
IA T<2cm, N=0, M=0 
IB T<2cm, N=small clusters, M=0 
IIA T<2 cm, N=1-3, M=0 or 
T= 2-5 cm, N=0, M=0 
IIB T=2-5 cm, N=small clusters 
T=2-5cm, N=1-4, M=0 
T>5cm, N=0, M=0 
IIIA N=4-9 with or without tumor or 
T > 5cm, N=small clusters or  
T>5cm, N=1-3, M=0 
IIIB T=any size, M=spread to chest wall and/or skin and/or N=9+ 
IIIC T=with or without, N=10+ or M: in nodes above or below the collar 
bone, axilla or near the breast bone 
IV M=other organs in the body 
 
In addition to stages, breast cancer is categorized in groups based on hormone 
receptor and human epidermal growth factor (HER2) status. Hormone receptor (HR) 
positive (ER+/ PR+) breast cancers have receptors on the cell walls that are sensitive to 
naturally occurring estrogen and progesterone. HR negative (ER-/PR-) breast cancer 
does not have hormone receptors on the outside walls of the cells. The HER2 gene is a 
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growth promoting protein that helps control breast cell growth (Anderson, Rodenberg & 
Katki, 2014). In breast cancer that involves the HER+ genotype, there is uncontrolled 
cell division and rapid growth of cancer cells. Luminal A breast cancer is ER+ and/or 
PR+ and HER2- and accounts for approximately 70% of diagnosed breast cancer 
(Anderson et al., 2014). Luminal B breast cancer is ER+ and/or PR+ and HER 2+. This 
is an aggressive type of cancer and accounts for approximately 10% of all breast 
cancers (Anderson et al., 2014). HER2 type breast cancer is ER-/PR- and HER2 + and 
makes up 5% of breast cancers (Anderson et al., 2014). Basal-like or triple negative 
breast cancer (ER-/PR-/HER2-) makes up 12% of breast cancers and is more 
aggressive than the Luminal A and B types (Anderson et al., 2014). These typologies, 
along with tumor profiling are used to guide treatments for breast cancer. 
Treatment for breast cancer may include surgery, radiation, hormone therapy, 
chemotherapy and/or targeted therapy (NCI, 2015). Surgery is used for stages I-IIIA to 
remove the primary tumor. Surgery may be a lumpectomy, breast conserving tumor 
removal, or mastectomy. Sentinel lymph node biopsy is used in conjunction with surgery 
to determine if cancerous cells have spread to the lymph system. Physical side effects 
of surgery include pain, tenderness and the development of scar tissue, which may 
result in limited range of motion and lymphedema. Surgery has traditionally preceded 
other types of adjuvant treatment for breast cancer. Recently, preoperative or 
neoadjuvant chemotherapy has come into greater use. The goal of neoadjuvant 
treatment is to shrink the tumor, which may make an unresectable tumor operable or 
downstage a tumor to allow for breast conservation (Schott & Hayes, 2012). 
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The goal of radiation therapy is to destroy any remaining disease in the breast 
tissue after surgery and prevent local recurrence. Short-term side effects of radiation 
may include swelling, skin changes such as burning, and fatigue. Possible long-term 
side effects of radiation are nerve damage in the arm, brachial plexopathy, 
lymphedema, and damage to the lungs and heart (Meric et al., 2002). Radiation 
treatment has been implicated in cognitive impairment, affecting verbal learning and 
memory, delayed recall, visual perception, and visual attention (Nguyen et al., 2013; 
Shibayama et al., 2014). Subsequent cognitive impairment may be related to fatigue or 
induced inflammation that elevates proinflammatory cytokines (Shibayama et al. 2014). 
Hormone therapy is a systemic therapy that is used with ER+ breast cancer. The 
drug, Tamoxifen, works to reduce the risk for recurrence by blocking estrogen receptors 
(Dalmau, Armengol-Alonso, Muñoz, & Seguí-Palmer, 2014). Side effects of tamoxifen 
include blood clots and bone thinning. Aromatase inhibitors (AIs), Femara, Arimidex and 
Aromasin, prevent the body from making estrogen in post-menopausal women by 
blocking an enzyme in fat tissue. Side effects of AIs include muscle pain, joint stiffness 
and pain. (Niravath, 2013). Hormonal treatment is recommended for five years or more. 
Hormonal treatments are associated with declines in cognition, specifically in the 
domains of visual and verbal memory (Bender et al., 2009). Functional impairment 
related to the use of hormonal treatments is not documented in published literature.  
Chemotherapy is a systemic treatment that kills fast growing cancer cells or 
stops them from dividing. Chemotherapy for breast cancer often consists of a 
combination of drugs given intravenously. There are five common regimes of 
chemotherapy: cyclophosphamide, doxorubicin and fluorouracil (CAF), 
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cyclophosphamide and doxorubicin (AC), cyclophosphamide, doxorubicin and taxol 
(AC-T), docetaxel, doxorubicin and cyclophosphamide (TAC) and taxotere or docetaxel 
and cyclophosphamide (TC) (NCI, 2015). Neoadjuvant chemotherapy is administered 
prior to the surgical removal of the primary tumor. Post-operative adjuvant 
chemotherapy is administered after surgical removal of the primary tumor. During 
chemotherapy individuals may experience hair loss, mouth sores, loss of appetite, 
nausea and vomiting, and fatigue. Long-term side effects of chemotherapy may include: 
menstrual changes, neuropathy, heart damage, hand-foot syndrome, decrease in 
cognitive functioning and fatigue (Howell, Jones & James, 2013). Neo-adjuvant 
chemotherapy is administered prior to surgery to shrink the tumor in more aggressive 
forms of breast cancer (stage III-IV). Targeted chemotherapies such as Trastuzumab 
and Pertuzumab block the HER-2 protein and are only used in individuals who test 
HER2+. Heart damage, hand and foot syndrome and fatigue are side effects associated 
with targeted chemotherapy.  
Purpose 
The original purpose of this study was to compare any changes in self-reported 
cognition to self-reported changes in functional performance among individuals with 
breast cancer following the completion of adjuvant chemotherapy or radiotherapy for 
breast cancer. Due to difficulty recruiting individuals receiving only radiotherapy and to 
maintain two groups for comparison, changes were made in the study design to include 
individuals receiving both chemotherapy and radiotherapy. This change limits the ability 
to make conclusions regarding the impact of radiation alone.  
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 The practical goals of this study are to offer evidence-based guidance to 
occupational therapists and other clinicians who serve community dwelling breast 
cancer survivors regarding the functional impairments, activity limitations and 
participation restrictions that survivors face in order to develop more meaningful and 
effective assessment methods and treatment plans. The original specific aims of this 
survey research with the changes in italics were: 
1. Measure changes in cognition for the chemotherapy and chemotherapy + 
radiotherapy groups over the 6 months following the completion of treatment. 
2. Compare any changes in cognition between the chemotherapy and 
chemotherapy + radiotherapy groups. 
3. Measure changes in functional performance for the chemotherapy and 
chemotherapy + radiotherapy groups over the 6 months following the 
completion of treatment. 
4. Compare any changes in functional performance between the chemotherapy 
and chemotherapy + radiotherapy groups. 
5. Compare any changes in cognition and changes in functional performance 
within each treatment group. 
6. Compare any changes in cognition and changes in functional performance 
between the treatment groups. 
In this study, cognition was operationalized as self-reported cognitive abilities 
and concerns. Functional performance was operationalized as self-reported physical 
function and social participation. The study assessed cognition and functional 
performance at three time points for women who have completed either chemotherapy 
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or chemotherapy + radiation therapy for breast cancer, comparing these parameters 
over time within groups and between groups. Assessment occurred at the conclusion of 
neoadjuvant chemotherapy (if not radiotherapy), adjuvant chemotherapy (if not 
radiotherapy), or radiation and 3 and 6 months afterward. The study used the Patient 
Reported Outcomes Measurement Information System (PROMIS®) to measure self-
reported changes in cognition and functional performance.  
The secondary aims for this study were: 
7. Compare changes in cognition and functional performance with mediating 
factors, including anxiety, depression, fatigue, sleep disturbance and pain 
interference.  
The Conceptual Model of Chemotherapy-Related Changes in Cognitive function 
recognizes the complex interplay of multidimensional factors affecting cognition after 
treatment (Hess & Insel, 2007). This model is addressed further in the literature review 
chapter. The PROMIS-57 scales of anxiety, depression, fatigue, sleep disturbance and 
pain interference were used to gather data about these mediating factors. Post-Hoc 
analysis explored trends over time in cognition and functional performance. 
8. Compare caregiver/significant others perceptions of cognitive impairment with 
self-reports of breast cancer survivors. 
Originally, I had hoped to compare subject self-ratings on the PROMIS 
instrument with caregiver surveys using the Patient Competency Rating Instrument, 
Caregiver Version (Wilson, 2004). This aim was not carried out. Caregiver referral was 
optional in the study. Only three participants provided contact information for a 
caregiver. No caregivers replied to the email invitations for the study.  
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Rationale 
Cognitive impairment associated with treatment for cancer is receiving significant 
attention within the literature and the oncology, rehabilitation and survivorship 
communities (Denlinger, et. al., 2014; Player, Mackenzie, Willis & Loh, 2014; Wefel, 
Vardy, Ahles & Schagen, 2011). The greatest attention has been directed to the 
population of breast cancer survivors. The National Comprehensive Cancer Network 
(NCCN) Clinical Practice Guidelines in Oncology- Survivorship: Cognitive Function 
Version 1.2014 (Denlinger, et. al., 2014) recommend occupational therapy as a first line 
intervention to address specific functional limitations associated with cognitive 
dysfunction. Within these guidelines, the lack of screening tools for assessment is 
acknowledged, and the panel recommends evaluation of cognitive impairment as a way 
to guide rehabilitation efforts. This study will help to inform the oncology community 
about any changes in self-reported cognition and functional performance over the six-
month time span immediately following the completion of chemotherapy or 
chemotherapy + radiotherapy for breast cancer. 
Theoretical Framework 
The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function 
developed by Hess & Insel (2007) is based on existing knowledge about cognitive 
impairment associated with all types of cancer. This model defines a constellation of 
factors and mediators that may lead to cognitive impairments and which result in 
functional performance limitations and decreased health-related quality of life. This 
model was expanded by Myers (2009) to include a greater recognition of the 
interrelationships and impacts of concurrent symptoms such as fatigue, pain and 
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depression. This study was based on findings by Hess & Insel (2007) and Myers (2009) 
that a confluence of factors causes PBCCI, and examined the relationship between 
cognitive changes and functional performance. This relationship is not well defined 
within either the original or revised model. The International Classification of 
Functioning, Disability and Health Core Set for breast cancer (World Health 
Organization, 2001), and the Model of Human Occupation (MOHO) (Kielhofner, 2008) 
served as lenses to view the relationship between cognitive impairment and functional 
performance.  
Summary 
PBCCI is a complex phenomenon and its true impact on functional performance 
in everyday life is not well understood. This study describes and compares changes in 
cognition and functional performance that may occur during the six months following the 
completion of chemotherapy or chemotherapy + radiotherapy for breast cancer. 
Additionally, this study compares changes in cognition following chemotherapy or 
chemotherapy + radiotherapy with changes in functional performance. The influence of 
mediating factors was explored. This study addresses a significant gap in the literature 
regarding the consequences of changes in cognition related to breast cancer treatment 
and functional performance. The study offers evidence-based insights on the impact of 
PBCCI on participation in daily activities that may assist occupational therapists in 
adapting assessments and interventions that will better assist breast cancer survivors in 
transitioning back to life’s roles and responsibilities after treatment. 
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Chapter 2: Literature Review  
 
Post breast cancer treatment cognitive impairment (PBCCI) is bothersome and 
troubling for cancer survivors and poses a challenge to clinicians who wish to determine 
the nature of its impact on everyday activity. As discussed in this chapter, PBCCI is 
characterized by deficits in short-term memory, attention, speed of processing 
information, judgment, reasoning, spatial perception, and verbal/nonverbal memory that 
may be noted in patients who have undergone treatment for breast cancer. Current 
research suggests that PBCCI negatively affects the everyday functioning of breast 
cancer survivors, however, the extent of impact has not been well quantified.  
This chapter provides an overview of conceptual models from the disciplines of 
occupational therapy and oncology nursing that have guided the study. An overview of 
PBCCI is presented, including postulates of etiology, and domains of cognition that are 
impaired. Next, commonly reported cognitive sequelae and associated functional 
limitations are discussed. As noted by occupational therapy researchers Hartman-
Maeir, Katz, and Baum (2009): “Cognition is embedded in many aspects of daily life 
where the individual is required to perform complex activities, formulate goals and carry 
them out effectively.”  Cognitive skills are crucial in everyday living and it is important to 
understand the impact of PBCCI on everyday functioning in order to develop treatment 
strategies that will improve the quality of life for breast cancer survivors. 
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Theoretical Foundations 
The Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function. 
The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function 
provides a means for examining “chemobrain” in regards to the relationship of 
physiological and psychosocial factors (Hess & Insel, 2007). Developed in the field of 
oncology nursing, the purpose of the model is to promote research into the mechanisms 
of cognition that may serve as a foundation for interventions aimed at improving 
cognitive functioning and overall wellbeing. This model defines two antecedents: 
physiological changes resulting from the treatment of cancer and psychosocial factors 
related to the experience of the diagnosis. Mediators of the physiological factors include 
the specific chemotherapy drugs used in treatment, their dose and duration, other 
medications taken, and radiation therapy and its associated toxicities. Psychosocial 
symptoms include anxiety, stress, depression, and distress (Hess & Insel, 2007). Hess 
and Insel (2007) point out that this is not an exhaustive list of symptoms. They assert 
that every individual will have a unique constellation of factors that may affect cognitive 
function. This model recognizes the potential impact of the following moderators or 
intervening variables: age, education, intelligence, genetic factors, and coexisting 
neurocognitive disorders. This model does not specifically include the impact of socio-
economic status and social supports. Hess & Insel (2007) specifically note “until the 
domains of cognitive function affected by cancer treatment are identified and 
instruments are used consistently to measure the domains, knowledge will not progress 
concerning the prevention or treatment of the problem” (p. 991). The intention of this 
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model is to develop an understanding of the consequences of chemotherapy-related 
declines in cognition in the context of health-related quality of life and functional ability.  
Green, Pakenham and Gardiner (2005) proposed a model of subjective and 
objective cognitive outcomes associated with cancer. The purpose of this model was to 
stimulate a greater understanding of the relationships among objective and subjective 
cognitive outcomes. Objective outcomes are those measured by neuropsychological 
tests and subjective outcomes are based in an individual’s perceptions of their quality of 
life. Cancer treatments, psychosocial factors, and physical health have direct 
relationships with emotional health and objective cognitive impairment, while emotional 
health and objective cognitive impairment have a direct relationship to subjective 
cognitive impairment. In comparison to Hess & Insel’s (2007) work, Green et al. (2005) 
provided a closer look at the relationship between the objective and subjective cognitive 
differences that are reported. A major shortfall of this model is that Green et al. did not 
discuss the outcomes of cognitive impairment in terms of function and health-related 
quality of life.  
Myers (2009) (see Figure 1) revised Hess & Insel’s (2007) model based on the 
Theory of Unpleasant Symptoms. This theory describes the interactions and 
relationships between physiological, psychological and situational factors on 
performance in the areas of functional status, cognition and physical performance 
(Myers, 2009). Functional status is similar to the concept of participation from the ICF. 
Myer’s revision of the Hess and Insel model includes an acknowledgement of the 
interrelationship of the timing, intensity, distress and quality of concurrent symptoms 
including fatigue, pain, and depression. Additionally, Myers included situational factors  
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Figure 1: The Revised Conceptual Model of Chemotherapy-Related Changes in 
Cognitive Function Based on the Theory of Unpleasant Symptoms.  
Note. From “ A Comparison of the Theory of Unpleasant Symptoms and the Conceptual Model of 
Chemotherapy-Related Changes in Cognitive Function” by J.S. Myers, 2009, Oncology Nursing Forum, 
36(1), p.E8. Copyright 2009 by the Oncology Nursing Society. Reprinted with permission. 
 
as mediators. These include lifestyle factors, employment type and status, diet, 
exercise, personal experience, marital status, and social support. While the revision 
provides a more comprehensive view of the “symptom experience of cognitive 
impairment” it minimizes the multidimensionality of the concurrent symptoms. Both the 
original and revised model are lacking in definitions of the consequences or outcomes 
of chemotherapy-related cognitive function. Radiotherapy is viewed as a mediator and 
its specific role in cognitive impairment is not defined within this model. No models exist 
to explain the relationship of non-CNS radiotherapy for breast cancer with cognitive 
impairment. This study addresses the relationship between changes in function and the 
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cognitive sequelae related to chemotherapy and chemotherapy + radiation treatment for 
breast cancer. The following theoretical models provide the framework and 
nomenclature for the functional consequences of PBCCI.  
International Classification of Functioning, Disability and Health. 
The World Health Organization’s (2001) International Classification of 
Functioning, Disability and Health (ICF), and the Model of Human Occupation (MOHO) 
(Kielhofner, 2008) provide a foundation for understanding how cognitive impairment 
post breast cancer impacts everyday functioning. The ICF also provides a systematic 
and uniform method to view the impact of cancer treatment on activities and 
participation. The ICF defines impairments as problems in body function or structure 
such as a significant deviation or loss. Activity is defined as the execution of a task or 
action by an individual. Participation is involvement in life situations. The ICF also 
considers the impact of both environmental and personal factors on an individual’s 
activities and participation.  
The ICF Core Set for breast cancer was validated in a study by Cooney, Galvin, 
Connolly & Stokes (2013). In this study, seven focus groups of a total of 34 women with 
breast cancer were utilized to confirm the ICF categories. Through these focus groups 
body functions in the categories of attention, memory, perceptual functions, and vision 
were identified by participants that were not included in the original breast cancer core 
set. These impairments in body structure and function result in activity limitations, such 
as the decreased ability to retain and make sense of verbal information and participation 
restrictions including the decreased ability to engage in work activities and social 
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relationships (Boykoff, Moieni & Subramanian, 2009; Jim et al., 2012; Player et al., 
2014). 
The Model of Human Occupation (MOHO). 
MOHO offers a holistic mechanism for viewing an individual’s function as a 
person transitions through the cancer diagnosis to survivorship continuum (Kielhofner, 
2008). Secondly, MOHO offers an occupation-based perspective on activities and 
participation that are defined in the ICF model. Occupations are a major contributor to 
quality of life. According to MOHO, at the point an individual is diagnosed with cancer 
he/she commences into occupational transition. It is during this time that the individual 
attempts to maintain or reestablish new activity routines. Under this model, occupations 
are viewed as a product of three interrelated constructs; volition, habituation, and 
performance capacity (Kielhofner, 2008).  
Volition is defined as “pattern of thoughts and feelings about oneself as an actor 
in one’s world which occurs as one anticipates, chooses, experiences, and interprets 
what one does” (Kielhofner, 2008, p.5). Humans have an innate desire to participate in 
occupations and volition encompasses the role an individual’s values play in 
determining the importance of participating and performing in chosen activities. 
Additionally, an individual’s sense of their capacities and effectiveness are important 
motivators for participation. The volitional process is a cycle, in which an individual 
makes a choice of occupation, experiences the activity, interprets the experience, and 
anticipates or reacts to future potentials. The volition for occupation has been 
demonstrated in a study of Icelandic women with breast cancer (Palmadottir, 2010). 
Women in this study expressed fear of losing the ability to be in active control of their 
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functional abilities and emotions. An emergent theme in several works is the desire for 
individuals with cancer to maintain control in order to participate in activities 
(Palmadottir, 2010; Sviden, G.A., Tham, K. & Borell, L. 2010).  
“Habituation is defined as an internalized readiness to exhibit consistent patterns 
of behavior guided by our habits and roles and fitted to the characteristics of routine 
temporal, physical and social environments” (Kielhofner, 2008 p. 18). Role performance 
is an important construct of habituation that may be impacted by PBCCI. The 
experience of breast cancer has been demonstrated to negatively impact the roles of 
parent, spouse, and worker (Boyle, 2006; Maunsell, Brisson, Dubois, Lauzier & Fraser, 
1999; Shands, Lewis, Sinsheimer & Cochrane, 2006). Maintaining routines is important 
to individuals with cancer and individuals become distressed when they are unable to 
perform daily routines (Cheville, A. 2005: Palmadottir, 2010; Svidén, Tham & Borell, 
2010). Resumption of activities of daily living and instrumental activities of daily living 
are equated with a return or maintenance of normalcy (Lyons, et al. 2010, Svidén, Tham 
& Borell, 2010).  
Performance capacity is comprised of the physical and cognitive abilities an 
individual possesses that enable him/her to do activities (Kielhofner, 2008). MOHO 
values the individual’s self-perceptions of functional ability. The cognitive functions such 
as memory, attention, planning, and processing speed all contribute to performance 
capacity. The three constructs -- volition, habituation, and performance capacity -- 
integrate with one another in the context of a multilayered environment to result in 
human occupation that is sustained through an organized pattern. Change occurs when 
an internal or external component is altered and results in a new pattern.  
 
 
19 
 
The ICF is a multidisciplinary model that provides a common framework for 
international collaboration and understanding of how health conditions relate to 
disability, while MOHO is discipline-specific to occupational therapy (Kramer, Bowyer & 
Kielhofner, 2008). Both models recognize the dynamic relationship between factors that 
contribute to an individual’s ability to perform everyday activities and participate in 
society. In regards to this study, the body function of cognition was studied in 
association with activities and participation.  
 The Conceptual Model of Chemotherapy-Related Changes in Cognitive Function 
and MOHO together provide a conceptual foundation for examining the impact of 
PBCCI on participation in occupations. The antecedents and mediators have the 
potential to significantly impact an individual’s volition, habits and performance capacity. 
The physiological factors and associated toxicities result in changes to the cognitive 
capacities of an individual. To understand the impact, both models call for self-report 
and formal assessment of the changes. “Persons with cancer frequently gauge their 
health or quality of life from an occupational perspective. They report feeling healthy or 
satisfied with life when they can do activities that are important to them” (Lyons, 2006 p. 
6). This sense of satisfaction is representative of occupational competence. 
Occupational competence is a construct of MOHO representing an individual’s ability to 
maintain routines and roles that are in line with one’s personal values resulting in 
personal satisfaction (Kielhofner, 2008).  
Post Breast Cancer Treatment Cognitive Impairment 
The phenomenon of PBCCI is commonly referred to as “Chemobrain” or 
“Chemofog”. Reports of chemotherapy-related cognitive impairment vary by type of 
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cancer (Hess & Insel, 2007; Raffa 2011). Cognitive problems are more frequently 
reported among breast cancer survivors than among ovarian cancer survivors (Hess & 
Insel, 2007). Cognitive problems have also been reported in populations of chemo-
therapy treated patients with brain tumors, lung cancer, acute myeloid leukemia and 
testicular cancer (Von Ah, Jansen, Allen, Schiavone & Wulff, 2011). Across cancer 
types and treatments, survivors have reported cognitive problems following treatment in 
the areas of complex attention, concentration, verbal and visual memory, and 
processing speed. These symptoms are similar to the cognitive changes often observed 
in individuals with human immuno-deficiency virus (HIV), mild traumatic brain injury, 
multiple sclerosis, congestive heart failure, Type 2 diabetes mellitus, chronic obstructive 
coronary disorder (COPD) and depression (Raffa  2011; Vardy, Rourke & Tannock, 
2007). Breast cancer has been the primary focus of research on cancer-related 
cognitive impairment (Hodgson, Hutchinson, Wilson & Nettleback, 2013; Holohan, Von 
Ah, McDonald & Saykin, 2013).  
Currently, there is not a consensus on the specific etiology of PBCCI. The first 
published report of cognitive impairment associated with chemotherapy appeared in the 
early 1980’s. Silberfarb (1983) described subtle losses in cognitive flexibility and the 
ability to think abstractly, as well as problems with word finding and forgetfulness, 
following chemotherapy for cancer. Initially, these symptoms were attributed to anxiety, 
depression and a predisposition of age toward delirium in cancer patients, and therefore 
the complaints of patients were not given much credence by physicians. Silberfarb 
(1983) likened the cognitive impairment experienced by cancer patients to delirium, “a 
relative global impairment of memory and thinking.”  In a second report focused on 
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breast cancer patients, Silberfarb (1984) hypothesized a multifactorial etiology 
consisting of chemotherapy, hypercalcemia, metabolic disorders, and cerebral 
metastasis. He also indicated possible roles of medications prescribed for pain, 
insomnia and anxiety in causing cognitive impairment.  
In 1997, van Dam et al. published a landmark study exploring cognitive function 
in Dutch women with breast cancer two years after the completion of chemotherapy. 
Three groups were compared, high-dose chemotherapy plus radiotherapy and 
tamoxifen (n=34), standard-dose chemotherapy plus radiotherapy and tamoxifen (n=36) 
and a control group (n=34) of women with stage 1 breast cancer who did not undergo 
chemotherapy. Concentration and memory problems were reported by a significant 
number of subjects in each treatment group (p=.006). The high dose group showed 
greater cognitive impairment, higher depression scores, and lower physical function, 
role function and social function scores. This study was the first to identify a correlation 
between chemotherapy dosage and “chemobrain” based on the results of 
neuropsychological testing. 
Despite a number of succeeding studies, we still do not know the definitive cause 
of cognitive changes among chemotherapy patients who have cancer (Ahles, 2012). 
Many early studies made the assumption that the cause was chemotherapy alone and 
did not take into consideration that most women receive additional treatments that may 
include surgery with general anesthesia, radiation therapy and endocrine therapy. A 
common postulate regarding the cause of “chemobrain” has been that chemotherapy 
agents cross the blood brain barrier and kill brain cells (Hess & Insel, 2007; Raffa, 
2011). This is unlikely, however, since common chemotherapy agents do not easily 
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cross the blood-brain barrier. This has been a major problem in treating brain 
metastases (Raffa, 2011). In trying to unravel what is happening in the brain to cause 
cognitive problems in daily living several other postulates are currently under study. 
Scientists are investigating direct neurotoxic effects, oxidative stress and DNA damage, 
induced hormonal changes, immune dysregulation and release of cytokines, blood 
clotting in small CNS vessels, and genetic predispositions (Ahles, 2012; The 
International Cognition and Cancer Task Force, 2014). Therefore, the use of a broader 
term such as PBCCI, is necessary to better describe cognitive impairment related to 
breast cancer treatment.  
 Less is known about the role of localized (non-CNS) radiotherapy in PBCCI. 
Studies of chemotherapy-related cognitive impairment using radiation groups as 
comparison have shown changes in different cognitive domains unique to each group. 
Nguyen et al. (2013) found the chemotherapy group to have changes in general 
cognitive function, working memory, psychomotor speed and executive function with the 
radiotherapy group demonstrating deficits in verbal learning, visual perception, visual 
attention and short-term retention. Quesnel et al. (2009) identified changes in self-report 
cognitive failures, verbal memory, and verbal fluency in the chemotherapy group, and 
only verbal memory changes in the radiotherapy group. Jim et al. (2009) found attention 
deficits in the radiotherapy group and impaired episodic memory in the chemotherapy 
group. One hypothesis is that inflammation resulting from non-brain radiation elevates 
circulating levels of pro-inflammatory cytokines which in turn are associated with 
negative changes in cognition, specifically verbal memory and delayed recall 
(Shibayama et al., 2014). Changes in verbal learning, visual perception, visual attention, 
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and short-term retention have been noted more than ten years after the completion of 
radiotherapy for breast cancer (Nguyen et al., 2013). Within the existing literature, it is 
difficult to delineate changes in cognition related to breast cancer treatment due to the 
lack of consistency in the domains of cognition that are measured.  
 An inductive process has been used to identify other contributors to PBCCI, 
suggesting that fatigue, depression, anxiety and hormonal changes may play either a 
causative or confounding role in PBCCI. Vearncombe et al. (2009) studied predictors of 
cognitive decline in 136 Australian women diagnosed with breast cancer and treated 
with chemotherapy and a control group of 21 women diagnosed with breast cancer that 
did not receive chemotherapy. The subjects in the chemotherapy group were tested 
prior to chemotherapy and one month post-chemotherapy. Of the chemotherapy group, 
16.9% showed cognitive decline in cognition 4 weeks post conclusion of chemotherapy. 
Declines in hemoglobin levels and increases in anxiety significantly correlated with 
multiple test impairment, a decline on two or more cognitive measures within the 
chemotherapy group. Jansen, Cooper, Dodd and Miaskowski (2011) reported similar 
findings in regards to a significant decrease in hemoglobin levels in a longitudinal study 
of 71 women undergoing a chemotherapy regime of AC (standard dose doxorubicin and 
cyclophosphamide) or AC+T (standard dose doxorubicin and cyclophosphamide + 
taxane). Significant increases were also noted in depression and fatigue scores, as well 
as decreases in subjects’ self-perception of cognitive functioning. Self-reported 
cognition was significantly associated with anxiety (p<0.001), depression (p<0.001) and 
fatigue (p<0.001) using within subject analysis. Bender et al. (2009) concluded that 
depression was a covariate as women who indicated greater depressive 
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symptomatology self-reported more cognitive problems. Biglia et al. (2011) found that 
higher levels of anxiety and depression were correlated with lower self-reported 
cognition measured on the Functional Assessment of Cancer Therapy Cognitive Scale 
(Fact-Cog 2).  
In regards to hormonal treatments and menopausal status, verbal memory 
impairments were noted in breast cancer survivors treated with anti-estrogens 
(tamoxifen, anastrozole or combined treatment) when compared with healthy controls 
(Jenkins et al. 2004). Bender et al. (2006) found that chemotherapy and tamoxifen 
combined treatment resulted in greater declines in visual and verbal memory in the year 
following treatment than in a chemotherapy only group. The subjects in the treatment 
groups of this study were all pre- or peri-menopausal while the non-treatment group did 
include women in menopause. Menopausal status differences may have skewed 
Bender et al.’s results as Jenkins et al. (2006) reported, in their 3-year prospective study 
of women with breast cancer in the UK, those who experienced treatment-induced 
menopause were at more risk for cognitive decline. This is an important finding as these 
women were younger and more likely to be dealing with different life tasks and roles 
than women who were post-menopausal.  
In contrast, Hedayati, Alinaghizadeh, Schedin, Nyman and Albertson’s (2012) 
prospective study found significantly lower memory scores for a chemotherapy group 
(n=18) but not for a hormone therapy group (n=45) when compared to a healthy control. 
It is difficult to determine if the changes are related to menopause status or hormonal 
treatment or both, as Bender et al.’s (2006) study included premenopausal women, 
Jenkins et al.’s (2006) study included both premenopausal and menopausal subjects 
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and Hedayati et al.’s sample consisted primarily of women who were in menopause. 
These studies support a confounding but not a definitive role for hormonal treatments 
and/or hormonal status in PBCCI. Menopausal status and the use of hormonal 
treatments were tracked in this study and analyzed as a covariant.  
Cognition and Breast Cancer 
Changes associated with chemotherapy.  
The following domains of cognitive function -- attention, memory, concentration, 
intelligence, verbal ability, psychomotor function, executive function and spatial ability -- 
have been assessed to determine levels of cognitive impairment associated with breast 
and other types of cancers (Falleti, Sanfillipo, Maruff, Weih & Phillips, 2005; Hess & 
Insel, 2007; Jim et al., 2012). Memory declines have been associated with 
chemotherapy treatment (Bender et al., 2006; Collins et al. 2013; Ganz et al., 2013; Jim 
et al., 2009; Mehnert et al., 2007; Nguyen et al., 2013; Quesnel et al. 2009). Working 
memory deficits in chemotherapy groups were identified in multiple studies (Collins et 
al., 2013; Mehnert et al., 2007; Nguyen et al., 2013). Declines in the domain of verbal 
memory were reported by Bender et al. (2006) and Quesnel et al. (2009). Jim et al. 
(2009) report problems in the domain of episodic memory. Several studies have noted 
general cognitive decline and self-reports of cognitive dysfunction among subjects who 
have had chemotherapy (Collins et al., 2013; Ganz et al., 2013; Jenkins et al., 2006; 
Mehnert et al., 2006; Nguyen et al., 2013; Quesnel et al., 2009). Combined 
chemotherapy and radiotherapy treatment has been associated with changes in 
executive functioning, processing speed, subjective memory complaints and mental 
fatigue (Ganz et al., 2013; Phillips et al., 2012).  
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A pair of meta-analyses have examined the severity and nature of cognitive 
findings for individuals with breast cancer treated with chemotherapy. Falleti et al. 
(2005) analyzed 6 breast cancer studies in order to estimate the magnitude of changes 
in attention, motor function, memory, executive function, language and spatial ability. 
Effect sizes were calculated for each domain, with a negative effect size indicating lower 
performance in the chemotherapy group compared to controls. The effect sizes ranged 
from small (0.2) to moderate (0.5) with average effect sizes of -0.03 for attention, -0.051 
for motor function, -0.26 for memory, -0.18 for executive function, -0.041 for language 
and -0.48 for spatial ability. There were significant associations between larger effect 
sizes across all domains and a shorter time since the culmination of chemotherapy, 
treatment with tamoxifen and younger patient age. The overall results of this meta-
analysis suggest mild cognitive impairment (Falleti et al., 2005).  
Jim et al. (2012) focused their meta-analysis on long-term changes in cognitive 
functioning experienced by breast cancer survivors. This meta-analysis included 17 
studies, 4 that were included by Falleti et al. (2005) and the remainder which were 
published after 2004. Sixty-nine neuropsychological tests were utilized across the 
included studies and were categorized into eight domains: attention, executive 
functioning, information processing, motor speed, verbal ability, verbal memory, visual 
memory and visuo-spatial ability. Subjects in the chemotherapy groups demonstrated 
significantly worse functioning in the domains of verbal ability (g -0.19) and visuospatial 
ability (g -0.27) in comparison to controls and pre-chemotherapy baselines. Overall the 
magnitude of effect sizes across domains was small. This study suggests that cognitive 
impairment associated with breast cancer is slight. In contrast with Falleti et al. (2005), 
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there were not significant impairments in motor function, memory and executive 
function. 
The meta-analyses discussed here are limited by the quality of the studies 
included, the wide variety of assessments used and small sample sizes that ranged 
from 18-97 subjects in chemotherapy groups. Additionally, there was no way to account 
for confounding variables, such as depression and anxiety. Jim et al. (2012) note that 
the longitudinal studies included in their meta-analysis may not have uncovered 
possible changes in cognitive functioning due to practice effects. Age, education, time 
since education and endocrine therapy were not associated with worse cognitive 
functioning by Jim et al. (2012), unlike the results of Falleti et al. (2005).  
Changes associated with radiotherapy.  
Changes in verbal memory, verbal learning, visual perception, visual attention, 
and executive functioning are associated with non-CNS radiation treatment for breast 
cancer (Jim et al., 2009; Nguyen et al., 2013; Phillips et al., 2012; Quesnel et al., 2009). 
These changes have been identified in studies in which a disease control of participants 
who received only radiotherapy was used for comparison to a chemotherapy group. 
Shibayama et al. (2014) set out to specifically examine changes in memory associated 
with radiation treatment. They identified lower levels of verbal memory and delayed 
recall in the radiation group when compared to a non-radiation group. A major limitation 
of this study was that approximately 50% of the radiation and non-radiation group had 
received chemotherapy and this was not controlled for in statistical analysis. Verbal 
learning, visual perception, visual attention and short-term retention were identified as 
long-term problems (greater than 10 years) in a radiation only breast cancer treatment 
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group when compared to women who had received chemotherapy and a non-cancer 
control group (Nguyen et al., 2013). These problems persisted when age was controlled 
for. This study did not control for endocrine therapy, which has been identified as a 
confounding factor in other studies. Moderate levels of attentional fatigue and a 
decreased capacity to direct attention as measured by self-report were found to persist 
over the course of radiotherapy extending out to 4 months after the conclusion of 
treatment (Merriman et al., 2010). These studies demonstrate a confounding role for 
radiotherapy in PBCCI, however none of these studies explored the impact of these 
cognitive problems on everyday activities and social participation.  
Changes in Functional Performance Associated with Breast Cancer 
Breast cancer treatment may cause a number of functional performance changes 
either aside from or in addition to cognitive changes. Functional performance includes 
changes in physical function and the performance of ADL’s, IADL’s, as well as social 
participation. In a systematic review of the literature, Ewertz and Jensen (2011) 
categorized problems associated with breast cancer treatment into three areas; focal 
problems, systemic problems, and psychosocial problems. Focal problems are related 
to therapies such as surgery and radiation. Lymphedema, pain and other arm and 
shoulder problems are included in this category. Systemic problems are attributed to the 
toxicities of chemotherapy and the side effects of endocrine treatment. Neuropathy, 
infertility, premature menopause and cardiovascular disease are common long-term 
systematic problems associated with breast cancer treatment (Ewertz & Jensen, 2011). 
Limited evidence is available about cancer-related neuropathy; however neuropathy is 
related to pain and sensory and motor impairment (Brearley et al., 2011, Ewertz & 
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Jensen, 2010). Evidence shows that chemotherapy treatment with a taxane produced 
deficits in motor function which were hypothesized as a result of peripheral neuropathy 
(Jansen, Cooper, Dodd & Miaskowski, 2011). Ewertz and Jensen (2011) delineate 
psychosocial problems as consequences of diagnosis and treatment, including 
depression, fear of recurrence, sleep disturbance, cognitive problems, fatigue, and 
sexual problems. 
Reduced arm function related to breast cancer surgery and radiotherapy has 
been linked to difficulties in performance of ADL’s and a lower health-related quality of 
life (Hayes et al., 2012). O’Toole et al. (2015) studied breast cancer related 
lymphedema’s impact on the ability to perform upper extremity activities of daily living. 
Their study followed 324 women who underwent unilateral mastectomy for 
approximately 30 months after surgery, finding lower functional scores, averaged from 
19 items from the DASH, associated with fear of lymphedema, pain, mastectomy and 
axillary node dissection. Fatigue has also been shown to impact daily living activities for 
women with breast cancer during treatment up to twelve weeks afterward (de Jong, 
Candel, Schouten, Abu-Saad & Courtens, 2006). This study of 157 women with breast 
cancer showed that for women who had mastectomies, lower levels of activities were 
correlated with greater levels of fatigue. This was not observed in the group who had 
lumpectomies. Both of these studies calculated scores for function, but they did not 
account for the involvement of multiple factors related to treatment such as anxiety, 
depression and pain.  
It is clear that surgical treatment for breast cancer can result in upper extremity 
physical impairments. These physical impairments include reduced upper extremity 
 
 
30 
 
range of motion and lymphedema. Pain and fatigue also contribute to reducing the 
ability to perform activities and maintaining social participation. The changes in upper 
extremity function may play a confounding role in measuring the cognitive domain of 
psychomotor speed as the tests that are used are typically pegboard tasks that require 
fine motor skills. 
Current literature does not specifically correlate functional performance problems 
post breast cancer with PBCCI. However, cognitive skills are needed in order to 
successfully perform most everyday activities. Ogilvy, Livingstone and Prue (2008) 
identified problems in the areas of food preparation, household chores, social activities 
and employment related to fatigue. This study did not examine the role of changes in 
cognition as it relates to activities and participation. Braithwaite et al. (2010) report that 
the presence of functional limitations post breast cancer treatment results in a 
decreased overall survival. Braithwaite did not address cognitive impairment in relation 
to functional limitations. Loss of functional independence is also a concern for women 
experiencing PBCCI, including the inability to participate in family activities and 
frustrations at work due to problems in reading, anxiety and memory problems (Player, 
et al., 2014).  
Changes in Functional Performance Associated with Cognition 
Several studies looking at breast cancer and work provide insight into the 
challenges attributed to changes in cognition. In a qualitative study of 74 breast cancer 
survivors, Boykoff, Moieni and Subramanian (2009) describe PBCCI in terms of difficulty 
digesting new information, decreased focus, concentration and speed. The participants 
reported that decreased focus led to difficulty with job performance. Similar issues at 
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work were reported in a qualitative study of 22 breast cancer survivors by Von Ah et al. 
(2013). This study identified issues in the domains of short-term memory, long-term 
memory, speed of processing, attention and concentration, language and executive 
functioning. Participants reported that they had to work harder and utilize compensatory 
strategies at work. Additionally, participants reported that they did not notice the extent 
of their cognitive issues until after the completion of chemotherapy. The deficits for 16 of 
22 participants did not improve over time (Von Ah et al., 2013).  
Decreased self-confidence at work resulting from problems with memory were 
identified by Munir et al. (2011) through their qualitative interviews of 31 breast cancer 
survivors. These qualitative studies demonstrate that women may have difficulty in work 
performance related to PBCCI. No existing literature was located describing the impact 
of cognitive impairments related to non-CNS radiotherapy for breast cancer and 
functional abilities. This study is the first to specifically focus on the relationship of 
changes in cognitive abilities associated with chemotherapy and radiotherapy treatment 
for breast cancer with changes in everyday functional performance. 
Conclusion 
The impact of PBCCI on activities and participation is not well understood. The 
majority of existing research has focused on establishing evidence for the changes 
through neuropsychological assessment and determining the etiology as it is related to 
physiologic mechanisms. Several major issues are noted in the literature:  
•  A working definition of cognitive function does not exist in relationship to cancer;  
• There is not a standardized diagnostic criteria for cancer related cognitive 
impairment;  
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• Current research focuses on different cognitive domains such as language, 
attention, processing, memory and concentration but not the impact on functional 
performance (Hess & Insel, 2007; Raffa, 2011; Von Ah et al., 2011).  
Occupational therapists specialize in enabling individuals to perform personally 
meaningful occupations. Current literature points to functional limitations resulting from 
PBCCI. However, these limitations have not been well quantified. Additionally, PBCCI is 
most often associated with chemotherapy. Individuals who have been treated with non-
CNS radiotherapy are also experiencing symptoms of PBCCI. This study measured 
self-report changes in cognitive abilities and concerns, functional abilities and social 
participation over 6 months following the completion of chemotherapy or chemotherapy 
+ radiotherapy for breast cancer. This study also examined the impact of confounding 
factors such as age, menopausal status, sleep disturbance, pain interference, anxiety 
and depression on functional ability and social participation. A better understanding of 
the functional impact of PBCCI may be useful in designing more effective interventions 
and facilitating optimal performance of occupations by breast cancer survivors.  
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Chapter Three: Research Methodology 
 
This study, as original proposed, aimed to compare self-reported cognitive 
function and everyday functional performance between two samples of patients with 
breast cancer who have received either adjuvant chemotherapy or radiotherapy, 
measured at the conclusion of treatment and 3 and 6 months later. Several months into 
participant accrual, no individuals receiving radiotherapy had enrolled. The dissertation 
committee was reconvened and approved the addition of a chemotherapy + radiation 
group. Therefore the two samples consist of individuals receiving only chemotherapy or 
those receiving chemotherapy + radiotherapy. The data from this study describe and 
measure changes in the domains of cognitive function and everyday functional 
performance over time in order to improve the predictive value of cognitive and 
functional screens in guiding occupational therapy interventions for this population. This 
study provides a better understanding of the extent to which PBCCI impacts the ability 
to perform daily activities, which thus far has not been well documented in published 
literature. This chapter describes the rationale, design, participant population, 
measurement tools, procedures, and data analysis plan. Chapter four provides an in 
depth description of challenges faced in recruitment and the changes made to the study 
to address the problems.  
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Approval 
The original research plan was submitted and approved by the Massey Cancer 
Center Protocol Review and Monitoring Committee Cancer Prevention and Control 
Subcommittee in January 2016 (MCC-15-12217). The study (HM20006120) was 
approved by the Institutional Review Boards of Virginia Commonwealth University by 
expedited review according to 45 CFR 46.110 on 3/31/2017 under Expedited category 
7. In April 2016, the study was approved by Exempt review through the Elizabethtown 
College Institutional Review Board. In August 2016 an amendment was approved to use 
Facebook for study recruitment, change eligibility requirements and to add a 
chemotherapy + radiation therapy group to the study. The rationale for these changes 
will be discussed later in the chapter. In February 2017 the study approved for 
continuation according to 45 CFR 46.108(b) and 45 CFR 46.109(e) and 45 CFR 46.110 
by VCU IRB Panel A.  
Design Rationale 
The Revised Conceptual Model of Chemotherapy-Related Change in Cognitive 
Function provides the foundation for this study. In summary, this model views Post 
Breast Cancer Cognitive Impairment (PBCCI) resulting from two primary antecedents, 
cancer treatment and cancer diagnosis (Myers, 2009; Hess, 2010). The two types of 
breast cancer treatment compared in this study include completion of surgery, and 
either chemotherapy or chemotherapy + radiotherapy. This conceptual model goes on 
to view changes in functional abilities and health-related quality of life as consequences 
of changes in cognitive function (Hess, 2010; Myers, 2009). The changes in cognition 
and everyday functional performance are of particular concern to occupational 
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therapists, as treatment would focus on a compensatory or remedial approach to 
restore functional abilities.  
Recommendations from the National Comprehensive Cancer Network (NCCN) 
Clinical Practice Guidelines in Oncology - Survivorship: Cognitive Function Version 
1.2014 (Denlinger, et. al., 2014) and the International Cognition and Cancer Task Force 
(ICCTF) (Wefel, et al., 2011) are also integrated in this study design. The NCCN clinical 
practice guidelines (Denlinger, et al., 2014) cite occupational therapy as a first line 
intervention for cancer related cognitive impairment, along with neuropsychology. 
Occupational therapy typically addresses the ability to perform activities of interest in 
daily life, and the impact of underlying client factors, in this case cognition (American 
Occupational Therapy Association, 2014). This study examined the functional 
consequences of Post Breast Cancer Cognitive Impairment (PBCCI) through the use of 
the PROMIS Cancer Physical Function Scale, Ability to Participate Scale, and 
Satisfaction with Participation Scale. The ICCTF guidelines recommend a disease 
specific comparison group to control for the relative effects of the combination of 
treatments that are administered for breast cancer (Wefel et al., 2011).  
In the original study proposal the radiotherapy group acted as the specific 
comparison group. A chemotherapy + radiotherapy treatment group was substituted to 
ensure that there would be a comparison group, as it was difficult to identify and recruit 
individuals receiving only radiotherapy. Nine individuals who were treated with only 
radiation entered the study. None qualified due to completing their course of treatment 
outside of the study parameters of the past 21 days. The study used a posttest-only 
design with nonequivalent groups (O’Farrell, et al., 2013; Shadish, Cook & Campbell, 
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2002). Both groups consisted of women who were diagnosed with breast cancer. One 
group consisted of those who had been treated with chemotherapy, and the other group 
consisted of those who had been treated with chemotherapy + radiotherapy. 
Functional performance is defined in this study as performance of activities of 
daily living (ADL’s) and instrumental activities of daily living (IADL’s), including social 
participation and roles. The impact of the performance of roles in the areas of family and 
work has been recently highlighted as a major issue for survivors of breast cancer as it 
relates to cognitive impairment and an individual’s ability to resume her/his prior lifestyle 
(Player et al., 2014). Therefore, the inclusion of the PROMIS Participation scales 
address role performance and satisfaction, in the areas of relationships, parenting, 
leisure and work (Bode, Hahn, DeVellis & Cella, 2010). This is also consistent with the 
Model of Human Occupation and the construct of habituation, as discussed in Chapter 
Two. 
Within the Revised Conceptual Model of Chemotherapy-Related Changes in 
Cognitive Function, changes in cognition and functional performance are impacted by 
the interplay of lifestyle factors, situation factors and concurrent symptoms. These 
factors and symptoms include age, educational level, fatigue, anxiety, depression, sleep 
quality and hormonal status, all of which were measured for study participants. The 
PROMIS 57 v.2 measured self-reports of anxiety, depression, pain, and sleep 
disturbance at each observation. The demographic questionnaire collected related 
information about age, stage of cancer, treatment, employment, educational level and 
comorbidities.  
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The original study proposal included a caregiver observation to provide additional 
insight into changes in functional ability and participation experienced after 
chemotherapy or radiotherapy for breast cancer, because awareness of cognitive 
function may be over- or under-estimated when an individual has cognitive impairment 
(Kolakowsky-Hayner, 2010). Providing a referral to a caregiver for participation was 
optional. No caregivers entered the study, so no data is available for comparison.  
Study Design 
This descriptive study used a longitudinal posttest-only design at three 
assessment time points with nonequivalent groups (Shadish, Cook & Campbell, 2002). 
The intent of this study was to explore the relationship between changes in self-reported 
cognitive abilities and cognitive concerns with changes in functional performance to 
better understand the phenomenon of PBCCI for breast cancer survivors who have 
completed either chemotherapy or radiotherapy. No individuals with radiotherapy 
enrolled in the study. The results compare a chemotherapy only group with a 
chemotherapy + radiation group. Participants in both groups were assessed at three 
time points, O1: at the completion of chemotherapy or radiotherapy (within 2-3 weeks to 
allow for recovery from immediate treatment effects) as a baseline, O2: 3 months post, 
and O3: 6 months post, in order to assess changes in cognition and function over time. 
Figure 2 provides an overview of the study flow for participants. This approach mirrors 
the common progression of clinical practice in occupational therapy, where a client’s 
level of function is evaluated upon referral, not prior to receiving treatment for cancer. 
Additionally, these time frames match with medical oncology follow-ups. Analysis of the 
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Figure 2: Study flow for participants beginning with enrollment. 
 
resulting data from each time point may help inform medical and rehabilitation providers 
of areas to be addressed with this population at common follow-up time points.  
Participants completed informed consent, demographics questionnaire, the 
PROMIS-57v2, the PROMIS Cognitive Abilities and Concerns Scales v1.0, PROMIS 
Cancer Physical Function Scale V1.0, PROMIS Ability to Participate in Social Roles and 
Activities (v2.0) and Satisfaction with Social Roles and Activities (v2.0) (See Appendix 
A-C) at O1. Subsequently, at the next two observations participants completed the same 
battery with a demographics update form.  
Determination of Variables 
Type of treatment, chemotherapy or chemotherapy + radiotherapy, is the 
independent variable (IV) for comparison between groups in relationship to the 
dependent or outcome variables. In regards to the complexity of PBCCI, the 
 Informed Consent
Eligibility Questionnaire
Observation 1
3 weeks post completion of 
treatment
Demographics
PROMIS 
Observation 2
3 months post completion 
of treatment
Demographic Update
PROMIS
Observation 3
6 Months post completion 
of treatment
Demographic Update
PROMIS
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constellation of breast cancer treatment factors is the IV or predictor variable in this 
study for within subject analysis. This constellation includes type of surgery, physiologic 
factors including type of chemotherapy agent, radiotherapy, hormonal status, and 
psychological factors including depression, anxiety, sleep disturbance, fatigue, and pain 
interference as defined by the Revised Conceptual Model of Chemotherapy-Related 
Changes in Cognitive Function (Myers, 2009).  
Cognitive function is a dependent variable for between and within group analysis. 
Cognitive function is measured in two ways, self-report assessment of cognitive abilities 
and self-report assessment of cognitive concerns via the PROMIS Applied Cognition - 
Abilities and the PROMIS Applied Cognition Concerns scales. These scales measure 
perceived functional abilities and concerns in the context of everyday activities, and the 
cognitive domains of memory, concentration, following directions, and learning. 
Functional performance is a dependent variable comprised of measures of physical 
function and social participation.  
Physical function is measured by the score on the PROMIS Cancer Physical 
Function scale v1.0. This scale contains questions about mobility, activities of daily 
living and instrumental activities of daily living. This scale measures an individual’s self-
reports of their ability to perform specific activities and is not an observation of actual 
performance. The instrument is designed for use with any type of cancer diagnosis 
(PROMIS, 2015a). Two aspects of the dependent variable of participation, ability and 
satisfaction, were measured, using the PROMIS Ability to Participate in Social Roles 
and Activities V2.0 and the Satisfaction with Roles and Activities V 2.0. These scales 
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measure aspects of role performance in the areas of work, family life, friendships and 
other personal responsibilities. 
Covariates include depression, anxiety, sleep disturbance, fatigue, and pain 
interference as measured by the PROMIS 57 Profile V2. Additional covariates including 
age, educational status, work status, stage of cancer, type of surgical intervention, 
concurrent treatments of hormonal, and/or targeted therapies, and lymphedema. These 
were measured through self-report on the demographics questionnaire. These 
covariates or moderators are included in the Revised Conceptual Model of 
Chemotherapy-Related Changes in Cognitive Function (Myers, 2009).  
Measures 
An enrollment questionnaire and demographics measure was created for this 
study (Appendix B). The collection of age, race and ethnicity follow current NIH 
guidelines. The demographics measure collected information on current employment 
status, caregiver status, menopausal status, stage of cancer including tumor size, 
number of positive lymph nodes, and metastasis, type of chemotherapy, type of surgery 
for breast cancer, tumor receptor status, and type of lymph node dissection, presence of 
lymphedema, radiotherapy, targeted therapy, and medical history including, anemia, 
thyroid disease, and vitamin D deficiency. The collection of demographics was based on 
factors included in Myers (2009) Revised Conceptual Model of Chemotherapy-Related 
Changes in Cognitive Function. 
The Patient Reported Outcomes Measurement Information System (PROMIS®) 
is a measure of health domains that can be utilized universally across different disease 
types. PROMIS® (PROMIS, 2015b) consists of banks of questions on physical, social 
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and mental health domains. The system is designed to provide a technological 
infrastructure that supports NIH-funded clinical investigations across Institutes, 
disciplines, diseases and subpopulations. PROMIS® instruments were developed using 
Item Response Theory (IRT) “a family of statistical models that link individual items to a 
presumed underlying trait or concept represented by all items in the item bank. 
(PROMIS, 2015 c).  
This study utilized the PROMIS v 1.0 Applied Cognition – Abilities and General 
Concerns scales, the Ability to Participate in Social Roles and Activities v 2.0, 
Satisfaction with Social Roles and Activities v 2.0, and the Physical Function Ca Bank, v 
1.1 and the PROMIS-57 Profile v2.0 (Appendix C). For all the PROMIS® scales the raw 
scores are converted to a standardized T-score for each subject. A T-score has a mean 
of 50 and a standard deviation of 10. The development of the PROMIS® scales 
specified procedures to ensure construct, concurrent and, criterion validity (PROMIS, 
2013).  
The PROMIS Applied Cognitive Abilities v1.0 and the PROMIS Applied Cognitive 
General Concerns v1.0 (Appendix C) were used as the self-report measure of cognition. 
The abilities scale is positively worded and asks the respondent to rate items about 
attention, memory, concentration and other cognitive tasks for the past 7 days on a 
scale of not at all, a little bit, somewhat, quite a bit and very much. The concerns scale 
is negatively worded or problem focused asking the respondent to rate difficulty or 
trouble with the same tasks on abilities scale. The questions are rated on a scale of 
never, rarely (once), sometimes (two or three times), often (about once a day) or very 
often (several times a day). Both scales place the cognitive domain within the context of 
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an everyday activity (PROMIS, 2015d). For example, new learning is represented as an 
ability in the item “I have been able to learn new things easily, like telephone numbers 
or instructions. The concerns scale has the question worded “I have trouble 
remembering new information, like phone numbers or simple instructions.” These scales 
are based on the Functional Assessment of Cancer Therapy-Cognitive Function scale 
(FACT-Cog) that was designed to measure both abilities and concerns (Lai, et al., 
2014). The PROMIS instruments were designed “to better understand cognitive function 
during and following cancer treatment from a patient’s perspective” (Lai, et al., 2014). 
These scales were developed with a sample of 509 participants. Items were generated 
through interviews and field testing. Conceptual models were tested using 
unidimensional and multidimensional item response theory. Results showed “separation 
in the clusters of factor loadings between concerns and abilities to support separate 
reporting of concerns and abilities” (Lai, et al., 2014). This was confirmed in the 
cognitive interviewing process of the instrument development. As such, this study used 
the conservative approach advocated by Lai, et al. and measured both concerns and 
abilities.  
Reliability and validity of the PROMIS cognitive scales has been assessed with 
individuals with multiple sclerosis, revealing high internal consistency with a reliability 
Cronbach α coefficient of .97 (Becker, Stuifbergen, Lee & Kullberg, 2014). Becker, et al. 
(2014) also found participants who were unemployed due to their disabilities reported 
lower cognitive abilities and greater concerns. This study measured both abilities and 
concerns related to cognition in order to get a fuller picture of the experiences of 
participants and any changes over the 6-month study period.  
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The PROMIS-Ca Physical Function Scale (Appendix C) was used to measure 
activities of daily living and instrumental activities of daily living. The participant rates 
their level of difficulty on each item from “no difficulty” to “unable to do”. The instrument 
covers activities inside and outside the home, including dressing, bathing, shopping, 
laundry, doing dishes and other household tasks as well as getting in and out of a car, 
traveling overnight and participation in sports. The adult cancer instrument was 
developed for use with any type of cancer diagnosis. This scale contains 45 items as 
compared to 38 in the general physical function scale (PROMIS, 2014a). Internal 
consistency for the 38 item general physical function scale is high with a Cronbach α of 
.99 (PROMIS, 2014a). The additional items on the cancer scale were developed by 
content experts to address items that may convey a different meaning to individuals with 
cancer and then calibrated with adult cancer patients (PROMIS, 2014a). The T-score of 
50 on this scale represents the norm of the calibration sample, not the national sample 
as other PROMIS scales do (PROMIS, 2014a). This instrument addresses the MOHO 
construct of performance capacity.  
The Ability to Participate in Social Roles and Activity scale (Appendix C) 
measures perspectives about the ability to perform roles in work, family and social 
environment (Bode, et al., 2010). The Satisfaction with Social Roles and Activity scale 
(Appendix C) looks at how well the individual is satisfied with the performance of family, 
work and social roles. For example, the abilities scale has the participant rate ability 
items such as: “I have trouble doing my regular daily work around the house, I have 
trouble meeting the needs of my family.” These items are rated as never, rarely, 
sometimes, usually and always. The satisfaction scale has the participant rate “I am 
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satisfied with my current level of family activities and I am satisfied with how much work 
I can do (include work at home).”  This scale addresses the MOHO constructs of 
habituation and role performance. The internal consistency of both scales is high with a 
Cronbach α of .99 (PROMIS, 2015e). These scales were calibrated with a sample that 
included more individuals with chronic illnesses, therefore, they do not reflect the 
average of the United States general population as many of the other PROMIS scales 
do (PROMIS, 2014e). 
The PROMIS-57 v2 scale (Appendix C) contains short form scales for anxiety, 
depression, fatigue, pain interference and intensity, physical function, sleep disturbance 
and the ability to participate in social roles and activities. This profile instrument includes 
“high information items” that have been ranked through Computer Adapted Testing 
(CAT) simulations and reviewed by content experts. The PROMIS-57 v2 is administered 
as short forms that “enable a more direct comparability across people or time” 
(PROMIS, 2015f). The anxiety scale asks how often, never, rarely, sometimes, often 
and always, in the past seven days a participant has experienced related feelings of 
worry, fear and uneasiness. The depression, fatigue, sleep disturbance, ability to 
participate in social roles and activities and pain interference use the same rating 
procedure. The physical function questions ask the participant to rate how difficult tasks 
such as walking and doing chores are and to rate their limitations on doing house work 
activities. The physical function scale of the PROMIS- 57 has overlapping items with the 
PROMIS-Ca Physical Function Scale. The PROMIS-Ca Physical Function Scale is used 
for analysis since it was developed with a population of individuals diagnosed with 
cancer. The computer administration was set up to avoid having participants answer 
 
 
45 
 
items more than once as there is overlap of the PROMIS 57 scales with the other scales 
being administered.  
Hypotheses 
The original purpose of this study was to examine changes in self-report 
cognition and everyday functional ability, as measured at three evenly spaced time 
points over the first six months after the completion of either adjuvant chemotherapy or 
radiotherapy for individuals with breast cancer. Due to challenges to enrollment, the 
study compares chemotherapy only to chemotherapy + radiotherapy groups. Study 
research hypotheses include:  
HA 1: Cognition, as measured by the PROMIS Applied Cognition abilities and 
concerns scales, will improve within each group across the three measurement time 
points. 
HA2: Functional performance as measured by the PROMIS Cancer Physical 
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS 
Satisfaction with Social Roles and Activities will improve within each group across 
the three measurement time points. 
HA3: Change in cognition will positively correlate with change in functional 
performance within each group. 
HA4: Cognition, as measured by the PROMIS Applied Cognition abilities and 
concerns scales will differ between the chemotherapy and chemotherapy + 
radiotherapy groups. 
HA5: Functional performance as measured by the PROMIS Cancer Physical 
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS 
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Satisfaction with Social Roles and Activities will differ between the chemotherapy 
and chemotherapy + radiotherapy groups. 
Participants 
Individuals diagnosed with Stage I-IIIa breast cancer were recruited for the 
originally proposed groups, adjuvant chemotherapy and radiotherapy. In August 2016 
recruitment was expanded to include individuals receiving both chemotherapy and 
radiotherapy. At this point in the progression of treatment the participants were eligible if 
they were receiving targeted therapies such as Herceptin, and/ or hormonal treatments 
(i.e. aromatase inhibitors or Tamoxifen). Although, concurrent treatments have been 
implicated in the constellation of causes for PBCCI, excluding individuals with 
concurrent treatments would have significantly decreased the ability to recruit subjects.  
Eligibility 
In order for a person to participate in this study he or she must have been 18 
years or older, diagnosed with breast cancer stages I-IIIa and nearing the end of either 
chemotherapy or radiotherapy. The original eligibility criteria was limited to having 
undergone surgical intervention (mastectomy or lumpectomy) prior to adjuvant 
chemotherapy. To improve accrual, the eligibility was changed to allow for neoadjuvant 
chemotherapy with surgery at a later time. Anthracycline/taxane-based adjuvant 
chemotherapy was required for participation. Limiting subjects to an 
anthracycline/taxane-based treatment reflects current oncology practice and helped 
eliminate variability due to type of chemotherapy. Subjects in the chemotherapy + 
radiotherapy group must have completed a fully prescribed course of radiation 
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treatment. Participants needed to understand and communicate in English at a level to 
access and complete the PROMIS and demographic questionnaires.  
Exclusion criteria included a diagnosis of Stage IIIB or 4 breast cancer, non- 
anthracycline/taxane chemotherapy regimens, a history of chemotherapy for any other 
type of cancer, a history of cognitive impairment related to a brain injury, stroke, 
dementia, epilepsy or a current or past disorder/ disease of the central nervous system, 
a history of substance abuse, presence of a developmental disorder impacting 
cognition, or a history of hospitalization for mental illness. Individuals with stage IIIb or 4 
breast cancer were not eligible, as they are more likely to receive longer and more 
intense treatment regimens.  
Recruitment 
Recruitment for this study was open from May 2016 through February 2017. A 
multi-pronged recruitment approach of convenience sampling with snowballing was 
used for this study. Oncology clinics that were part of the Johns Hopkins Medical Center 
and Andrews & Patel Associates in the Harrisburg, Pennsylvania area were provided 
flyers (Appendix D) and agreed to distribute the flyers for the study. The Young Survival 
Coalition (YSC), a national organization based in New York City, advertised the study in 
their electronic newsletter and on their Facebook page. Additionally, YSC and Living 
Beyond Breast Cancer, a national organization based in Philadelphia,  allowed for a 
study announcement posting in their closed Facebook Support Groups. In October YSC 
posted a guest blog that discussed my journey from breast cancer survivor to 
researcher. This blog post contained a link to the study (Appendix D). 
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A Facebook page titled ‘The impact of breast cancer treatment on cognition 
research study’, @chemoandcognition, was created for this study. This page was linked 
to Facebook announcements as well as shared with personal friends and breast cancer 
survivors for snowballing. Posts were made on this page with reminders that the study 
was still open. Additionally, articles and blogs were shared on the topic of cognition and 
breast cancer. The decision was made not to use Facebook paid advertisements as 
they could not be targeted precisely enough to reach eligible individuals.  
Study announcements were emailed to twenty one face-to-face support groups in 
the state of Pennsylvania (Appendix E). One hundred twenty five flyers were distributed 
to attendees at the 2016 Young Survival Coalitions Midwest Symposium in Minneapolis, 
MN and 200 flyers at the West Coast Regional Symposium in Long Beach, CA. 
Additionally, ten flyers were given to individuals at the San Antonio Breast Cancer 
Symposium in December 2016 for nurses and advocates to distribute. It was expected 
that recruitment would occur over a period of 2-3 months. In total recruitment was open 
for 8 months. The plan to recruit through clinics and local support groups combined with 
online recruiting was an attempt to reduce coverage error by capturing both social 
media users and non-users (Dillman, Smyth & Christian, 2014).  
Participants were recruited prior to the completion of chemotherapy or radiation 
in order to initiate the first administration of assessments approximately 2-3 weeks post 
completion of treatment. The time span of 2-3 weeks provided for flexibility, allowed for 
immediate side effects of the chemotherapy or radiotherapy to clear, but still reflected 
the baseline cognitive and functional status at the conclusion of treatment. Prior to 
enrollment in the study, volunteers were asked to complete an informed consent and 
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eligibility questionnaire. These were available through a public link to the VCU 
REDCapTM System. The flyer provided an option to call or email for a paper copy of the 
consent form and survey. No participants requested this option. Each eligible participant 
was asked to recommend a caregiver to participate. Only three participants provided a 
caregiver referral. One caregiver referral was the same as a participant and was not 
contacted. The other caregivers were contacted via email and did not respond. Table 2 
provides an overview of the participant timeline, tasks and time commitment.  
Table 2 
Participant Timeline 
Observation Required Tasks Estimated Time 
Commitment 
Actual Time 
Commitment 
Study Entry Informed Consent  2-5 minutes 
O1: 
Completion 
of treatment 
(within 3 
weeks) 
Demographics 
PROMIS 
assessments 
Incentive form. 
30-45 minutes 15-35 minutes 
O2: 3 
months post 
O1 
Update of 
demographics 
PROMIS 
assessments 
30-45 minutes 
 
10-30 minutes 
O3: 6 
months post 
O1 
Update of 
demographics 
PROMIS 
assessments 
30-45 minutes 
 
10-30 minutes 
 
Sample Size 
 The original proposal had the goal of recruiting approximately 46 individuals for 
each group in this study to achieve a reasonable number of participants anticipated to 
complete the six-month study (n=32/group). This corresponds to an approximate 30% 
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attrition rate. This rate is similar to the attrition rate reported by Bender et al. (2006) in 
their 6-month study of cognition and breast cancer. The sample size was determined 
based on feasibility of recruitment and time constraints. If 32 subjects per group 
completed the study, then there would be 80% statistical power to detect a difference 
between the groups on the order of 0.8 standard deviation units (Cohen’s d = 0.8, 
considered a moderate-to-large large effect size). In August 2016, the recruitment goal 
was adjusted to achieve a sample size of 16 in each group, which corresponded to a 
one SD difference. The final sample size for this study was 16 with seven chemotherapy 
subjects and nine chemotherapy + radiation subjects. 
Attrition 
The risk of attrition was significant as this study followed participants over the 
span of six months. Several strategies were employed to reduce the potential loss. 
Participants were scheduled for O2 upon completion of O1 and for O3 at the completion 
of O2. Participants were sent automatic email from REDCapTM. If a participant did not 
respond I sent an additional reminder originating from REDCapTM. Participants were 
provided a $10 gift card or donation to YSC incentive upon completion of the first 
survey. This amount served as a small thank you token and was not at the amount to be 
viewed as coercive (Singer & Couper, 2009). Advance token incentives have been 
shown to be effective in improving response rates through establishment of trust and 
creation of a social exchange (Dillman et al., 2014). Advance incentives have been 
shown to increase response rates more than lotteries and those offered for completion 
(Dillman et al., 2014). These incentives were funded through an internal faculty grant 
from Elizabethtown College. During the study, participant progress on surveys was 
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monitored through REDCapTM. If a participant did not complete any surveys an email 
reminder was sent to invite the respondent to return to REDCapTM and complete the 
survey.  
Data Collection 
Study data were collected and managed using REDCapTM electronic data 
capture tools hosted at Virginia Commonwealth University (Harris et al. 2009). 
REDCapTM. (Research Electronic Data Capture) is a secure, web-based application 
designed to support data capture for research studies, providing 1) an intuitive interface 
for validated data entry; 2) audit trails for tracking data manipulation and export 
procedures; 3) automated export procedures for seamless data downloads to common 
statistical packages; and 4) procedures for importing data from external sources. Upon 
IRB approval an account was established in REDCapTM.  
A welcome page was set up with access to the informed consent and 
demographic survey (Appendix A-B). The study was set up into two arms. The first arm 
included the welcome, informed consent and eligibility survey. The second arm was for 
eligible individuals. As fields were created in REDCapTM  they were designated as 
private health information as necessary and data permissions were set up to maintain 
participant confidentiality. Automatic invitations were set up in the system to invite 
participants to complete their first survey three weeks after the treatment finish date 
provided in the eligibility survey. REDCapTM generated a unique link for each participant. 
The system was set up to send email invitations with a personally unique URL to the 
second arm of the study. The second arm contained the demographic surveys and 
PROMIS® instruments. The PROMIS® instruments were available in the 
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REDCapTM shared library and were uploaded into the study (Obeid et al 2013). The 
instruments were programmed to capture Computer Adaptive Testing (CAT) scoring 
(Cella, Gershon, Bass & Rothrock, 2014). In CAT the survey questions are adapted by 
the computer based on the responses provided on a previous question. CAT decreases 
administration time, while maintaining measurement precision (PROMIS, 2015g). The 
PROMIS® instruments were set up to avoid redundancy in asking the same item 
multiple times in each administration. Prior to launching, the project was tested by 
myself and a research assistant/ graduate student from Elizabethtown College.  
Statistical Analysis 
Data collected through REDCapTM was downloaded into an Excel worksheet. 
Data was cleaned and examined for outliers and missing data. The REDCapTM format of 
the PROMIS instruments required participants to complete all items, therefore there was 
no missing data in this section. Missing data from demographic questionnaires are 
indicated in the results section. The data was then uploaded into SAS for analysis. 
Descriptive statistics are provided in Chapter 5 for all demographics and scales to 
provide a picture of the sample. These include measures of central tendency and 
variance.  
The original proposed data plan was to use univariate and multivariate repeated 
measures analysis of covariance (RM ANCOVA) to compare the changes in cognition 
and functional performance variables within groups (HA1-3). This was changed to linear 
mixed effects models for HA1-2 and a correlation matrix comparing changes in cognition 
related variables with changes in functional performance variables for HA3. For the 
between group analysis (HA4-5), the groups were not matched within the study design; 
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therefore, the original analysis plan used propensity scores to account for the inability to 
randomly assign participants to treatment groups (Austin, 2011). Due to the small 
sample size (N=16) and attrition, linear mixed-effects models were calculated instead. 
This approach allowed for both within and between subject analyses and accounted for 
the repeated measures. In ANCOVA analysis, missing time point data results in 
dropping all the data from analysis. The linear mixed-effects model allowed for the 
inclusion of data from eight participants that missed one time point data collection.  
Likewise linear mixed-effects modeling was used to examine changes in fatigue, 
pain interference, sleep, anxiety and depression both within and between groups. The 
small sample size was not adequate to perform the proposed exploratory ANCOVA 
analysis to examine the impact of education level, sleep disturbance, pain, depression 
and anxiety on T-scores.  
This chapter provided an overview of the study design and the changes that were 
implemented in the areas of recruitment and data analysis. The following chapter will 
provide an in depth presentation of the challenges encountered in recruitment and 
enrollment in the study and the actions taken to address the associated issues. The 
study results are presented in Chapter 5 and discussed in Chapter 6.  
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Chapter Four: Study Recruitment and Enrollment Challenges 
“If it doesn’t work, it’s not failure, it’s data.” 
-Dorie Clark 2017 
 
In designing research, we typically try to foresee and address threats to validity 
and completion of research. These are weighed in relationship to resources available 
such as time, money, infrastructure, and researcher capacity. In the design of this study, 
efforts were made to balance rigor in research methods with the reality of the disease of 
breast cancer treatment profiles and the availability of eligible research subjects. This 
chapter provides an overview and discussion of the challenges and obstacles faced in 
the enrollment phase. The process of responding to these challenges and the actions 
implemented in an attempt to improve enrollment are presented.  
Challenges in Recruitment 
The proposed design of this study aimed to compare changes in cognition and 
everyday functional performance of individuals receiving chemotherapy treatment for 
breast cancer to those receiving radiation therapy. The radiation only arm served as the 
comparison group to control for the relative effects of the combination of treatments 
(Wefel et al., 2011). In order to limit variability and promote homogeneity, regarding type 
of chemotherapy, eligible participants must have received an anthracycline/ taxane 
based treatment. Additionally, original eligibility required surgery prior to the initiation of 
treatment. Initial recruitment was through flyer distribution to patients at Andrews & 
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Patel in Central Pennsylvania, Johns Hopkins Medical Center and e-newsletter/ social 
media posting by the Young Survival Coalition (YSC). The study announcement 
provided options to go online or to obtain paper surveys for participation. A dedicated 
phone number was established. The announcements by YSC provided a direct link to 
the study informed consent form.  
Recruitment initially relied on the cooperation of clinicians, doctors and nurses, to 
provide flyers to eligible patients, but this approach did not work effectively. Results 
from a focus group study examining the barriers to clinical trial recruitment describe “a 
hidden recruitment element’ in which it is necessary to gather support from other 
personnel at the clinical site (Stein et al. 2015). Furthermore, Stein et al. report that 
investigator/clinicians found it difficult to balance and integrate their own research with 
their clinical care. In this study, clinicians were being asked to recruit for a study that 
they were not personally invested in. It is possible that issues of this nature impacted 
distribution of flyers by medical professionals in this study. 
A second recruitment challenge may have been that the clinic flyers placed the 
onus on the participant to either go online or call the researcher to enroll in the study. In 
retrospect, this approach most likely led to the loss of potential participants. Cancer 
treatment is stressful and tiring. Patients may have put the flyer aside instead of taking 
the next step. In an effort to encourage flyer distribution, beginning in June 2016 
through February 2017, and monthly follow up emails were sent to both clinic contacts 
to encourage recruitment. The clinical liaisons replied to all inquiries stating that they 
would continue to encourage clinic staff to distribute flyers. This points to another issue 
within the study, the lack of tracking for flyer distribution. The clinical sites offered to 
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make their own copies to distribute. If numbered flyers were sent to the site, the site 
liaison would have been able to easily report the number of flyers distributed. 
The ability to recruit participants for this study within a reasonable time frame 
was overestimated. This common tendency of researchers, especially novice or junior 
researchers, is referred to as a ‘funnel effect’ or Lasagna’s Law (Gul & Ali, 2010; Stein 
et al. 2012). Low enrollment and nonresponse rates can prolong the time of studies, can 
lead to invalid or inconclusive results secondary to diminished statistical power, results 
in poorly used human and material resources and threatens the internal and external 
validity of research studies (Carlisle et al. 2015; Gul & Ali, 2010; Williams, Tse, DiPiazza 
& Zarin, 2015).  
Insufficient accrual of participants for clinical trials is often a top reason for 
termination. In 2013, a review of the ClinicalTrials.gov database found 57% of 619 trials 
terminated for nonscientific reasons resulted from insufficient rate of accrual (Williams et 
al. 2015). A study utilizing the National Library of Medicine clinical trial registry identified 
481 (19%) out of 2579 studies terminated for less than 85% of expected enrollment 
(Carlisle et al. 2015). Finally, volunteers participate in research studies to contribute to 
meaningful scientific knowledge. When studies are not sufficiently enrolled an ethical 
issue arises in regards to the volunteers and may deplete the available pool of 
participants (Carlisle et al, 2015; Williams et al. 2015). 
Efforts to Expand Enrollment 
Within two months of opening enrollment to the study, it became apparent that 
many interested participants were not qualifying for the study. In July a page for the 
study was created on Facebook (https://www.facebook.com/ chemoandcognition/) and 
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an amendment to the study IRB was submitted and approved. The study link was 
shared on two closed Facebook support groups. This resulted in over twenty new logins 
to the survey. The initial analysis of participant characteristics showed that interested 
participants were ineligible due to receiving both chemotherapy and radiation, or 
because they were receiving neoadjuvant treatment. The dissertation committee was 
reconvened in August 2016 and the study design was altered to include a 
chemotherapy and radiation treatment group, as well as including individuals receiving 
neoadjuvant treatment. The protocol changes were approved by the VCU IRB. 
Individuals who completed the consent process and were then eligible to participate 
were emailed and invited to return to the study.  
In addition to the changes in protocol, recruitment efforts were expanded. 
Twenty-one in person support groups in the state of Pennsylvania were contacted via 
email between June and September 2016 (Appendix E). Three groups responded and 
agreed to distribute the study flyer. Study announcements were posted in eight closed 
Facebook support groups with permission from the group administrator. Closed groups 
on Facebook require approval to join and individuals must demonstrate that they have 
been diagnosed with breast cancer. Monthly re-posts of the study announcement were 
made between August 2016 and January 2017. 
Posting on Facebook was intentionally made within closed support groups. This 
did not prevent the link from being shared. In Mid-July 2016 over a span of three days, 
56 records were created on REDCapTM. Evidently the link was shared and there were 
attempts to gain access to receive the incentive gift card. The eligibility screening 
questionnaire worked well in this case. Responses for date of diagnosis and end of 
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treatment dates needed to match up in order to qualify. This type of misrepresentation is 
associated with the lack of face-to-face contact in the recruitment process and is a clear 
risk associated with the use of Facebook for recruitment (Pedersen & Kurz, 2016). The 
low yield and completion rate observed in this study is consistent with other studies 
utilizing Facebook for recruitment (Kapp, Peters & Oliver, 2013; Ramo & Prochaska, 
2012). 
One hundred and twenty five flyers were distributed at the Young Survival 
Midwest Symposium in June 2016 and 200 copies at the West Coast Symposium in 
October 2016. In October, 2016 a guest blog was posted on the YSC website about my 
journey from breast cancer survivor to doctoral student researcher which included a link 
to the study (Appendix D).  
In November, 2016 an electronic flyer was emailed and 20 paper copies were 
mailed to committee member Dr. Albrecht for distribution through her clinic work setting. 
Additionally, three local nursing oncology groups were emailed with a request to 
distribute flyers and to make a presentation at their local meetings. One group replied 
stating they would distribute the flyer to their members. A presentation to the Oncology 
research group at Penn State Hershey Medical center was given in November 2016 and 
both medical oncologists and radiation oncologists agreed to distribute flyers. An 
electronic copy of the flyer was sent to research group coordinator and twenty paper 
flyers were passed out at the meeting. In December 2017, an electronic copy and 5 
paper flyers were provided to an oncology nurse in San Francisco and to the Cancer 
Resource Center in Ithaca, NY.  
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Eligibility Challenges 
The initial study design required that participants had surgery prior to initiating 
chemotherapy or radiotherapy. This design did not recognize a shift in breast cancer 
treatment toward the use of neoadjuvant chemotherapy and/ or radiotherapy, treatment 
provided before surgery, and negatively impacted enrollment. Of the first 50 individuals 
to start the enrollment process in the study three did not qualify because they were 
receiving neoadjuvant treatment. Additionally, comments to the Facebook 
announcements indicated interest among individuals who were ineligible because they 
had not had surgery prior to chemotherapy.  
The study design was based on the traditional approach in which breast cancer 
is treated with surgery and adjuvant treatment of chemotherapy, and/or radiation 
therapy, and/or endocrine therapy. The recent shift to neoadjuvant chemotherapy allows 
oncologists to determine if an individual has a pathologic complete response (pCR), 
meaning that there is no tumor left after the treatment. A pCR is associated with a 
survival benefit (Teshome & Hunt, 2014). With newer molecular technology, 
neoadjuvant treatment models identify both exceptional responders and non-responders 
(Chatterjee & Erban 2017). This approach also improves rates of less-invasive breast 
conservation surgery, quicker recovery and post-operative complications such as 
lymphedema (Chatterjee & Erban 2017; Steenbrugen et al. 2017; Teshome & Hunt, 
2014). Shifts in standards of care, such as experienced with this study, are known to 
impact clinical accrual (Carlisle, Kimmelman, Ramsay & MacKinnon, 2015). The 
inclusion of individuals with surgery before or after chemotherapy treatment introduces 
additional confounding variability. The study protocol was changed in August 2016, with 
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committee approval, to include individuals receiving neoadjuvant treatment. With this 
change five participants entered and completed the study.  
Technology Issues 
 At least ten times during data collection there was a glitch in REDCapTM and the 
survey queue failed to load automatically for participants. One participant emailed 
regarding the problem. Additionally, the problem was observed through monitoring of 
REDCapTM confirmation emails. The VCU REDCapTM administrators were contacted 
regarding this issue and they confirmed it was a problem within the entire 
REDCapTM system. When this occurred, an invitation to return and complete the survey 
was sent to the participant via REDCapTM. This strategy helped to reduce missing data 
in these instances.  
Summary 
Throughout the recruitment phase of the study the researcher was responsive to 
recruitment challenges and attempted to develop new sources for participants. Prior to 
implementation, strategies were discussed with the dissertation advisor and/or 
committee. When necessary, IRB amendments were submitted for approval. Despite 
these best efforts, the desired sample size was not met. This study included the 
following barriers to enrollment: a significant number of eligibility criteria, reliance on 
clinic staff to provide flyers to eligible patients, and reliance on volunteers to go online to 
enroll in the study. Positive recruitment efforts included modifying eligibility, adding 
recruitment sites and support group outreach.  
The following chapter provides a summary of the progression of participants 
through the study and the results of the study. Demographics, descriptive data and 
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hypothesis analysis are provided. Chapter 6 provides a discussion of the results in the 
context of current published literature, study limitations and implications of this study for 
occupational therapy and oncology professions.  
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Chapter Five: Results 
 
 The purpose of this study was to better understand the impact of PBCCI on 
activities and participation during the six months following the conclusion of 
chemotherapy and/or radiotherapy for breast cancer. In this study participants receiving 
either chemotherapy or chemotherapy + radiotherapy completed online self-report 
surveys regarding their physical function, social function, cognition and related 
confounding factors including sleep interference, pain, depression, fatigue and anxiety, 
at the conclusion of treatment, and at three and six months later. This descriptive study 
utilized a longitudinal post-test only design with nonequivalent groups (Shadish, Cook & 
Campbell, 2002). In this chapter, the study results are presented, beginning with an 
overview of the participants followed by descriptive data framed by Hess & Insel’s 
(2007) Conceptual Model of Chemotherapy-Related Changes in Cognitive Function 
concluding with the hypothesis related analysis.  
Participants 
Participants were recruited through clinics, snowballing, support groups, and 
Facebook. Sixteen women, ages (28-45) participated in this study. The majority of these 
participants (n=12, 75%) are considered younger women (age<40 years) in the 
oncology field (Gabriel & Domchek, 2010). Nine received chemotherapy + radiotherapy 
and seven received chemotherapy. Nine women that received radiotherapy only 
completed the consent process, but were ineligible due to being more than 3 weeks out 
 
 
63 
 
of treatment. Recruitment for this study was challenging and an in-depth review of 
recruitment procedures and challenges is provided in Chapter 4. Figure 3 provides an 
overview of the progression of participants in the study and reasons for ineligibility. 
There was an overall 50 percent attrition rate over the six month follow up. The 
chemotherapy group had an initial enrollment of n=7, decreasing to n=3 at the three 
month follow up and n=2 at the six month follow up. In the chemotherapy + radiotherapy 
the initial enrollment was n=9, decreasing to n=7 at three months and n=6 at six 
months.  
Cancer Related Demographics 
Table 3 provides an overview of breast cancer related demographics. The table 
covers diagnosis, treatment and physiologic factors that are known to be involved in 
cognitive changes associated with cancer treatment (Hess & Insel, 2007; Myers 2009). 
Two participants in the chemotherapy group had zero positive lymph nodes and five did 
not report a number of positive nodes. In the chemotherapy + radiotherapy group, one 
participant reported zero positive nodes. The other participants in this group ranged 
from 1-7 positive nodes. This is expected as radiotherapy is more prevalent when there 
is lymphatic involvement.  
Situational Factors 
In the Conceptual Model Of Chemotherapy-Related Changes in Cognitive 
Function, Hess and Insel (2007) define the situational factors of lifestyle and personal 
experience. Lifestyle includes employment, and personal experience includes marital 
status and social support. Fifteen women identified themselves as white and one as 
other. All the women in the chemotherapy + radiotherapy group were married (n=9), one  
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Entered REDCapTM
N=149
Initiated Informed Consent
 N=106
Incomplete Contact Info
n=14
Completed Informed 
Consent 
N=92
Diagnosed previously with another type of 
cancer
n=3
Stage I-IIIa 
Breast Cancer N=89
Stage IV 
Breast Cancer
n=1
Duplicate entries
n=20
Epilepsy n=1
Learning Disability n=1
History of Substance Abuse n=1
Hospitalization for Mental Illness n=1
Finished Treatment > 3 weeks 
prior to enrollment
n=43
Chemotherapy + 
Radiotherapy 
prior to eligibility change
 n=5
Included in Analysis
 O1
N=16
Chemotherapy n=7
Chemotherapy + Radiotherapy 
n=9
Radio-
therapy
n=9
Blank Consent
n=43
O2
N=12
Chemotherapy n=5
Chemotherapy + Radiotherapy 
n=7
O3
N=8
Chemotherapy n=2
Chemotherapy + Radiotherapy 
n=6
 
Figure 3: Participant enrollment and retention. 
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Table 3 
Demographics: Antecedents and Physiologic Mediators According to the Revised 
Conceptual Model of Chemotherapy-Related Changes. 
 Chemotherapy 
(n=7) 
Chemotherapy + 
Radiotherapy 
(n=9) 
Total 
(N=16) 
Stage of Cancer at Diagnosis I: 2 
II: 5 
III: 0 
I:2 
II: 4 
III: 3 
I: 4 
II: 9 
III: 3 
Surgery Type    
Lumpectomy 0 3 3 
Simple Mastectomy 4 3 7 
Modified Radical Mastectomy 0 4 4 
Type of Chemotherapy    
Standard AC-T 1 2 3 
Dose-Dense AC-T 2 1 4 
TAC 2 2 4 
TC 0 1 1 
Other 2 3 5 
Tumor Characteristics    
ER+ 0 8 8 
ER- 4 1 5 
PR+ 2 5 7 
PR- 4 1 5 
HER2+ 0 0 0 
HER2- 4 6 10 
Menopausal status at diagnosis    
Pre-menopause 6 9 15 
Peri-menopause 1 0 1 
Menopausal status at start of 
study 
   
Pre-menopause 3 0 3 
Peri-menopause 1 0 1 
Post-menopause 0 2 2 
Chemo-induced menopause 3 7 10 
Type of Hormonal Therapy    
Tamoxifen 0 1 1 
Zoladex 2 0 2 
Lupron 1 1 2 
Arimidex 0 2 2 
Aromasin 0 1 1 
Lymphedema Diagnosis 3 2 5 
Low Levels of Vitamin D 4 3 7 
Anemic at start of study 1 2 3 
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woman in the chemotherapy group (n=7) reported living with a partner, the others were 
married. None of the participants reported that they smoke or vape. Table 4 provides an 
overview of the education status and Table 5 shows employment status. A total of 7 
participants (chemotherapy n=2, chemotherapy + radiotherapy n=5) reported their 
employment status changed after their diagnosis with breast cancer. Four participants in 
the chemotherapy group were parents compared with six in the chemotherapy + 
radiotherapy group. One participant in the chemotherapy group reported caregiving for 
an adult. 
Table 4 
Education Level. 
   
 
Doctoral or 
Professional 
Degree 
 
 
 
Master 
Degree 
 
 
 
Bachelor 
Degree 
 
 
 
Associate 
Degree 
Post-
Secondary 
Non-
degree 
Award 
 
Some 
College 
No 
Degree 
 
 
 
 
Total 
Chemotherapy  0 2 2 0 1 2 7 
Chemotherapy 
+ 
Radiotherapy 
 1 1 4 1 1 1 9 
Total  1 3 6 1 2 3 16 
 
Table 5 
Employment Status. 
 Full-time Part-time Volunteer Homemaker Total 
Chemotherapy 4 2 0 1 7 
Chemotherapy 
+ 
Radiotherapy 
6 1 1 1 9 
Total 10 3 1 2 16 
 
Psychosocial Factors 
 Stress, depression, anxiety and distress are psychosocial factors associated with 
cognitive changes in the Conceptual Model Of Chemotherapy-Related Changes in 
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Cognitive Function (Hess & Insel, 2007). Depression and anxiety may also be a 
concurrent symptom related to cancer treatment that impacts health-related quality of 
life. Participants were asked if they had a history of anxiety and if they had a history of 
depression. Six participants reported a history of anxiety, one in the chemotherapy 
group and four in the chemotherapy + radiotherapy group. Four individuals reported a 
history of depression, all in the chemotherapy + radiotherapy group. Two participants in 
the chemotherapy group did not answer this question.  
PROMIS® Descriptive Data 
Each participant completed the PROMIS® instruments measuring cognition, 
physical function, social participation, anxiety, depression, fatigue, pain interference, 
and sleep interference at the three time points. Table 6 provides a summary for each 
domain for the chemotherapy group and the chemotherapy + radiotherapy group at 
each observation point. Using Computer Adaptive Testing (CAT) in REDCapTM, 
participant scores were automatically converted from raw scores to a standardized T-
score. For all PROMIS® measures, the T-score has a mean of 50 and a standard 
deviation of 10. The PROMIS-57 Profile v2.0 contains scales to measure depression, 
anxiety, fatigue, sleep interference and pain interference (PROMIS 2015f). These 
scales were normed on the general population of the United States. Higher scores 
represent more of the concept being measured and lower scores represent less. 
Fatigue and anxiety were one standard deviation higher than the norm for the general 
population of the US for the chemotherapy + radiation group, across all three time 
points. Depression scores were one standard deviation higher than the norm for the  
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Table 6 
Summary of T-Score Means on PROMIS Domains. 
  Observation 1 
(Baseline) 
Observation 2 
(3 Months) 
Observation 3 
(6 Months) 
PROMIS Domain Chemo 
n=7 
Chemo+Rad 
n=9 
Chemo 
n=4 
Chemo+Rad 
n=7 
Chemo 
n=2 
Chemo+Rad 
          n=6 
Physical Function Mean 44.96 42.59 48.20 43.17 52.80 42.93 
Median 43.9 42.90 45.20 41.40 54.10 43.50 
Cognition- 
Concerns 
Mean  36.59* 41.22  37.18* 42.56  38.45* 45.72 
Median 42.60 39.60 37.25 41.20 38.45 42.25 
Cognition- Abilities Mean 49.10 44.24 50.98 43.27 46.40  38.83* 
Median 48.50 43.60 51.75 43.50 46.40 41.45 
Ability to Participate Mean 46.21 47.68 51.35 44.40 54.60 46.77 
Median 43.80 47.80 48.85 44.70 54.60 51.20 
Satisfaction with 
participation 
Mean 50.91 45.77 50.23 43.30 48.15 44.58 
Median 48.00 45.80 51.55 44.30 48.15 49.05 
Depression Mean 59.07 57.64 55.25   60.70** 57.75   61.85** 
Median 59.80 57.60 58.40 62.25 57.75 59.60 
Anxiety Mean 58.16   61.10** 57.50   66.05**   61.20**   67.17** 
Median 60.00 63.40 60.25 67.45 61.20 67.80 
Fatigue Mean 56.66   62.28** 52.80   61.30** 55.50   61.58** 
Median 57.50 61.20 53.40 60.90 55.50 61.95 
Pain Interference Mean 59.07 55.89 49.65   60.70** 50.85 58.18 
Median 62.80 56.40 49.35 61.60 50.85 54.05 
Sleep Interference Mean 52.43 56.41 49.65 55.22 48.60 59.47 
Median 51.10 56.30 49.35 53.45 48.60 59.10 
Note. PROMIS® T-Scores have a mean of 50 and a standard deviation of 10. * One standard deviation 
below the PROMIS® instrument population norm. **One standard deviation above the PROMIS® 
instrument population norm.  
 
three and six month time points. This means the participants in this sample report 
higher levels of fatigue, anxiety and depression than would be expected.  
The PROMIS Physical Function Ca Bank v1.1 was calibrated with individuals 
diagnosed with different types of cancer (PROMIS 2015a). The PROMIS Ability to 
Participate in Social Roles v2.0 and PROMIS Satisfaction with Social Roles and 
 
 
69 
 
Activities v2.0 scales were calibrated with individuals with chronic illness that were 
sicker than the general population (PROMIS 2015e). The PROMIS Applied Cognitive 
Abilities v1.0 and the PROMIS Applied Cognitive General Concerns v1.0 were 
calibrated on samples enriched for chronic illness (PROMIS, 2015d). In this study, the 
chemotherapy only group was more than one standard deviation below the norm on the 
cognitive concerns scales across the six month span of the study (see Table 6). This 
may be interpreted as the group having fewer concerns than the normed population 
which was enriched for individuals with chronic illnesses. Cognitive ability t-scores for 
the chemotherapy + radiotherapy group did not change significantly during the study but 
fell to one standard deviation below the norm at the six month follow up. This result 
shows lower cognitive abilities than expected for a chronically enriched population  
Hypothesis Tests 
HA 1: Cognition, as measured by the PROMIS Applied Cognition abilities and 
concerns scales, will improve within each group across the three measurement time 
points.  
There was no significant change in cognition for either group over the six months 
post treatment as measured on either the abilities scale or the concerns scale (See 
Table 7). Cognitive concerns were one standard deviation lower than the PROMIS norm 
across all three time points for the chemotherapy only group, meaning this sample 
reported lower level of concerns with cognition.  At the six month follow up the 
chemotherapy + radiotherapy group was one standard deviation below the norm for 
cognitive abilities.  This may be interpreted as the group having lower cognitive abilities 
than expected. 
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Table 7 
Linear Mixed Effects Model Summarizing Changes in Cognition as Measured by the 
PROMIS Applied Cognition Scales According to Treatment Group Over The Six Months 
Following the Completion of Treatment. 
 
 
Estimate Standard 
Error 
df t-
Value 
PR>ItI 
Chemotherapy Slope 
Cognition- Concerns  1.6971 1.3756 14  1.23 0.2376 
Cognition- Abilities -0.4419 1.5505 14 -0.29 0.7798 
Chemotherapy+Radiotherapy Slope 
Cognition- Concerns -0.4751 0.6919 14 -0.69 0.5035 
Cognition- Abilities -0.9322 0.9953 14 -0.94 0.3649 
Note. Slope estimates were calculated using mean changes in PROMIS ® T-scores at the three time 
points- three weeks post treatment, three months post treatment and six months post treatment.  
 
 
HA2: Functional performance as measured by the PROMIS Cancer Physical 
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS Satisfaction 
with Social Roles and Activities will improve within each group across the three 
measurement time points. 
 Physical function as measured on the PROMIS scale improved significantly in 
the six months post treatment in the chemotherapy only group, but not in the 
chemotherapy + radiotherapy group. Ability to participate, as measured on the PROMIS 
scale, improved significantly for the chemotherapy + radiation group, but not for the 
chemotherapy only group. There was no significant change for either group in 
satisfaction with social roles and activities (see Table 8). 
HA3: Change in cognition will positively correlate with change in functional 
performance within each group 
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Table 8 
Linear Mixed Effect Model Summarizing Changes in Functional Performance by 
Treatment Group Over the Six Months Following the Completion of Treatment. 
 
 
Estimate Standard 
Error 
df t-
Value 
PR>ItI 
Chemotherapy Slope 
Physical Function  3.3142 1.2340 14  2.69 0.0178* 
Ability to Participate  3.3969 2.4752 14  1.37 0.1915 
Satisfaction with Social 
Roles 
-0.6809 2.6353 14 -0.26 0.7999 
Chemotherapy + Radiotherapy Slope 
Physical Function  1.8450 0.9147 14  2.02 0.0633 
Ability to Participate  2.8475 1.2976 14  2.20 0.0447* 
Satisfaction with Social 
Roles 
 
 1.8454 1.6475 14  1.12 0.2815 
Note. Slope estimates were calculated using mean changes in PROMIS ® T-scores at the three time 
points- three weeks post treatment, three months post treatment and six months post treatment.  
*significant at p<0.05 
 
A Pearson’s correlation matrix was used to examine the correlation of changes in 
cognitive variables with changes in the functional performance variables for eachgroup 
over time. A 95% confidence interval (CI) was calculated to determine significance of 
the correlations. The correlations provide only descriptive data about the direction of 
relationships. All correlations fell within the 95% CI for the chemotherapy + radiotherapy 
group, this was not the case for the chemotherapy only group. Appendix F contains the 
95% CI tables for all variables in both groups.  
Table 9 provides a summary of all correlations for the chemotherapy group.  
Of the three constructs used to define functional activity, physical activity, ability to 
participate and satisfaction with participation, only physical activity showed a significant  
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Table 9 
Chemotherapy: Correlations among Mean PROMIS® T-score Changes over Six Months 
Post Treatment. 
Variable 
Physical 
Function 
Cognitive 
Concerns 
Cognitive 
Abilities Depression Anxiety Fatigue 
Pain 
Interference 
Sleep 
Interference 
Ability to 
Participate 
in Social 
Roles 
Physical 
Function 
         Cognitive 
Concerns -0.6661* 
        Cognitive 
Abilities 0.6252 -0.6075 
       Depression -0.5265 0.5471 -0.7156* 
      Anxiety -0.7559* 0.8321* -0.6556* 0.5068 
     Fatigue -0.7306* 0.6864* -0.7484* 0.5675 0.6574* 
    Pain 
Interference -0.6693* 0.3967 -0.4655 0.4364 0.4986 0.6283 
   Sleep 
Interference 0.5154 -0.4826 0.5019 -0.5203 -0.5584 -0.5584 -0.5765 
  Ability to 
Participate 
in Social 
Roles 0.7338* -0.5461 0.6192 -0.5592 -0.4834 -0.6222 -0.4823 0.3759 
 Satisfaction 
w ith Social 
Roles -0.4048 0.4504 -0.5841 0.4088 0.4745 0.5306 0.4449 -0.3473 -0.4956 
 Note. Appendix F contains a full listing of the 95% Confidence Intervals. 
*significant at p<.05 
 
negative correlation (p<.05) with cognitive concerns, r=.-.66, 95% CI [-.91, -.05]. 
Likewise, a similar relationship of a significant negative correlation was observed for 
these two constructs in the chemotherapy + radiotherapy group (see Table 10). The 
chemotherapy + radiotherapy group showed a significant (p<.05) negative correlation 
for cognitive concerns and the ability to participate in social roles r=-.59, 95% CI [-.79, -
.27]. Within the chemotherapy + radiotherapy group, cognitive abilities were 
significantly, positively correlated with these two variables. This means as cognitive 
concerns decreased or lessened over time and cognitive abilities improved over time, 
physical function and ability to participate in social roles improved. An inverse  
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Table 10 
Chemotherapy + Radiotherapy: Correlations among Mean PROMIS® T-score Changes 
over Six Months Post Treatment. 
Variable 
Physical 
Function 
Cognitive 
Concerns 
Cognitive 
Abilities Depression Anxiety Fatigue 
Pain 
Interference 
Sleep 
Interference 
Ability to 
Participate 
in Social 
Roles 
Physical 
Function 
         Cognitive 
Concerns -0.6917* 
        Cognitive 
Abilities 0.6551* -0.6367* 
       Depression -0.5659* 0.5821* -0.7377* 
      Anxiety -0.7781* 0.8455* -0.6864* 0.5536* 
     Fatigue -0.7542* 0.7118* -0.7698* 0.6061* 0.6917* 
    Pain 
Interference -0.6994* 0.4483* -0.5132* 0.4895* 0.5507* 0.6651* 
   Sleep 
Interference 0.5722* -0.5387* 0.5592* -0.5799* -0.6456* -0.6155* -0.6331* 
  Ability to 
Participate 
in Social 
Roles 0.7478* -0.5877* 0.6396* -0.5834* -0.5158* -0.6437* -0.5148* 0.4261* 
 Satisfaction 
w ith Social 
Roles -0.4366* 0.4781* -0.6047* 0.4404* 0.5041* 0.5555* 0.4765* -0.3945* -0.5164* 
Note. Appendix F contains a full listing of the 95% Confidence Intervals. 
*significant at p<.05 
 
relationship occurred in respect to the correlation of cognition and the satisfaction with 
participation in social roles. As cognitive concerns lessened over time and cognitive 
abilities improved, satisfaction with participation in social roles increased. No causation 
or significance may be determined from correlational analysis. 
HA4: Cognition, as measured by the PROMIS Applied Cognition abilities and 
concerns scales will differ between the chemotherapy and chemotherapy + radiotherapy 
groups. 
The linear mixed-effects model was used to compare the slopes of the cognition 
variables for the chemotherapy group with the chemotherapy + radiotherapy group. No 
significant differences were observed between the two groups over time for cognitive 
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concerns (Estimate: 2.1723, SE: 1.5397, DF: 14, t: 1.141, PR>ItI 0.1801) and cognitive 
abilities concerns (Estimate: 0.4903, SE: 1.8425, DF: 14, t: 0.27, PR>ItI 0.7941). 
HA5: Functional performance as measured by the PROMIS Cancer Physical 
Function Scale, the PROMIS Ability to Participate Scale, and the PROMIS Satisfaction 
with Social Roles and Activities will differ between the chemotherapy and 
chemotherapy + radiotherapy groups. 
No significant differences between the two groups were observed on the 
functional performance variables when analyzed in the linear mixed-effects model as 
seen in Table 11. 
Table 11 
Comparison of Chemotherapy and Chemotherapy + Radiotherapy Groups on 
Functional Performance 
 Estimate Standard 
Error 
df t-
Value 
PR>ItI 
Physical Function  1.4692 1.5361 14  0.96 0.3551 
Ability to Participate  0.5494 2.7919 14  0.20 0.8468 
Satisfaction with Social 
Roles 
-2.5263 3.1079 14 -0.81 0.4299 
 
Exploratory Analysis of Psychosocial Factors and Concurrent Symptoms 
Depression and anxiety are viewed as both psychosocial factors and concurrent 
symptoms in the Revised Conceptual Model of Chemotherapy-Related Changes in 
Cognitive Function (Myers, 2009). Fatigue and pain interference are considered 
concurrent symptoms. Sleep interference is not specifically mentioned in this guiding 
model, but is included as a construct in the PROMIS-57 and was included in this study’s 
analysis. Table 12 provides a summary from the linear mixed-effects model examining  
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Table 12 
Slope Estimates for Psychosocial Factors and Concurrent Symptoms Within and 
Between Treatment Groups.  
 
 
Estimate Standard 
Error 
DF t-
Value 
PR>ItI 
Chemotherapy Slope 
Depression -2.7139 2.2720 14 -1.19 0.2521 
Anxiety  1.2185 1.5136 14  0.81 0.4343 
Fatigue -0.2326 2.1281 14 -0.11 0.9145 
Pain Interference -3.5960 2.1679 14 -1.66 0.1194 
Sleep Interference -0.6226 1.5570 14 -0.40 0.6953 
Chemotherapy + Radiotherapy Slope 
Depression -2.1571 1.3080 14 -1.65 0.1214 
Anxiety  0.8805 0.8326 14  1.06 0.3082 
Fatigue -3.3835 1.2210 14 -2.77 0.0150* 
Pain Interference  0.7311 1.3360 14  .055 0.5929 
Sleep Interference  1.2085 0.9488 14  1.27 0.2235 
Chemotherapy Vs Chemotherapy + Radiotherapy 
Depression -0.5567 2.6216 14 -0.21 0.8349 
Anxiety  0.3381 1.7275 14  0.20 0.8477 
Fatigue  3.1509 2.4535 14  1.28 0.2199 
Pain Interference -4.3271 2.5465 14 -1.70 0.1114 
Sleep Interference -1.8311 1.8233 14 -1.00 0.3323 
Note. Slope estimates were calculated using mean changes in PROMIS-57 T-scores at the three time 
points- three weeks post treatment, three months post treatment and six months post treatment.  
*significant at p<.05 
 
depression, anxiety, fatigue, pain interference and sleep interference. There were no 
significant differences between groups on these five constructs. 
Fatigue was significant (Table 12) in the chemotherapy + radiotherapy group with 
fatigue decreasing in the six months following treatment. Mean t-scores for fatigue were 
above 60 for all time points in this group (Table 10). This is one standard deviation 
greater than the general population of the United States. Although there were not 
significant changes over time for anxiety and depression in this group, their T-scores 
were also one standard deviation below the norm (Table 10).  
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Summary 
 In summary, the sample (N=16) in this study is considered young (ages 28-45) in 
regards to breast cancer research. Depression, anxiety and fatigue were at least one 
standard deviation higher than the normal US population in the chemotherapy + 
radiotherapy group. A significant improvement in physical function was found in the 
chemotherapy only group in the 6 months post treatment. Ability to participate in social 
roles and activities significantly improved in the chemotherapy + radiation group. 
Fatigue was a significant symptom for the chemotherapy + radiation group. There were 
no significant differences between the groups on any of the constructs measured in the 
study. There were no significant changes in self-reported cognition over the course of 
the study in either group. The following chapter will discuss these results and the study 
limitations within the context of current evidence and provide recommendations for 
future research and occupational therapy practice.   
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Chapter 6: Discussion 
 
 The goal of this study was to better understand how cognition and functional 
performance change after breast cancer treatment in order to better inform occupational 
therapists and oncology professionals about the challenges breast cancer survivors 
face after treatment in returning to their life’s roles and responsibilities. The original 
proposal for this study intended to compare individuals who underwent chemotherapy 
for breast cancer to individuals who received only radiotherapy for their breast cancer at 
3 evenly spaced time periods in the six months after completion of treatment. It became 
apparent several months into the study enrollment that it was going to be challenging to 
enroll the radiotherapy only group. The study enrollment criteria were expanded to 
include a group of individuals that received both chemotherapy and radiotherapy which 
served the purpose of maintaining a comparison group. The sample size (N=16), with 
seven participants in the chemotherapy group and nine participants in the 
chemotherapy + radiotherapy group, limits the ability to generalize results and draw 
conclusions from this study.  
Much can be learned from both the process of research and study design 
employed in this study. In this chapter an overview of the findings placed in the context 
of study aims and existing literature will be presented. Next, the limitations of the study 
will be discussed followed by a summary of implications for occupational therapy 
research and practice, and suggestions for further research.  
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Cognitive Performance Findings 
 The primary aims of this study were to measure changes in cognition and 
functional performance over the 6 months following the completion of treatment for 
breast cancer and to compare the changes between the two groups. Survivors of breast 
cancer report problems with cognition for many years after treatment. It is not clear how 
the reported changes in cognition impact the ability to participate in everyday activities. 
In this study, cognition was measured in terms of concerns or negative effects, and 
abilities or positive effects. There were no significant differences between the 
chemotherapy only group and the chemotherapy + radiotherapy group in regards to 
either measure of cognitive functioning. Neither group showed significant changes in 
cognition over the 6 months after the conclusion of treatment. This is in contrast to the 
study hypothesis predicting an improvement in cognition over time. It was surprising that 
the chemotherapy group was one standard deviation below norms on the PROMIS 
Applied Cognition Cognitive Concerns scale across all three time points. In the 
chemotherapy + radiotherapy group, there was a decline in cognitive abilities that 
dipped to one standard deviation below normal at the six month follow up. If 
chemotherapy is the primary contributor to cognitive impairments then one would expect 
for cognition to improve as the drugs clear the system. Consideration must be made for 
other physiologic, psychosocial and situational factors that are simultaneously impacting 
cognition and functional ability.  
Within the published literature, self-reported cognitive declines are common for 
women who have been diagnosed with breast cancer and undergone treatment (Collins 
et al., 2013; Ganz et al., 2013; Jenkins et al., 2006; Quesnel et al., 2009). Anecdotal 
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self-reports of cognitive problems occurred during recruitment for this study in response 
to the Facebook recruitment postings in closed support groups. Survivors that were too 
far out of treatment to participate provided encouragement and shared their challenges 
in their comments:  
“Cool, We’re not dead yet” 
 “I’m struggling with short term memory loss” 
“I have been out of treatment since 2007 but was wondering how you managed 
to go back to school? I was on 26 at dc, now 35 and I want to but am terrified bc I 
still have cognitive issues” 
“If u ever do 5yrs out id love to help. Because im affected everyday” 
Functional Performance Findings 
 Within current published literature there is a gap in the understanding of 
resumption of functional performance for cancer survivors. Functional performance as 
narrowly defined in terms of physical impairments and the ability to perform basic 
activities of daily living, as measured in previous studies, stops short of considering the 
full spectrum of activities humans participate in (Brearly et al., 2011; Jansen et al., 2011; 
O’Toole et al., 2015). Several qualitative studies have explored areas of instrumental 
activities of daily living and employment (Braithwaite et al., 2010; Ogilvy, Livingstone & 
Prue, 2008; Player et al., 2014). This is the first study to quantitatively look at cognitive 
performance and functional performance in broad terms including physical abilities, 
social participation and personal satisfaction with social participation.  
Functional performance was represented by the constructs of physical function, 
ability to participate in social roles and activities, and satisfaction with social roles and 
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activities in this research. In the six months following treatment the chemotherapy only 
group showed significant gains in physical function. For both groups the mean T-scores 
were lower than 50 which is below the average for a general cancer population (but 
within 1SD). The chemotherapy group reported higher levels of physical functioning 
than the chemotherapy + radiotherapy group, however this was not a significant 
difference. In a 6 month longitudinal study of breast cancer survivors, Jansen et al. 
(2011) reported greater deficits in motor function associated with taxane based 
treatment (Jansen et al. 2011). All participants in this study received a taxane based 
chemotherapy treatment.  
The chemotherapy + radiotherapy group showed significant positive changes in 
their ability to participate in social roles and activities over the six month time period 
after treatment. There was not a significant change in the reported satisfaction with 
participation in social roles and activities in either group. Occupational therapists are 
concerned with both the ability to participate in meaningful activities and an individual’s 
satisfaction. The levels of anxiety, depression and fatigue were one standard deviation 
higher than the norms for the general US population. These concurrent psychosocial 
factors may potentially be impacting satisfaction.  
Psychosocial Factors and Concurrent Symptoms 
 An additional aim of this study was comparison of changes in cognition and 
functional performance with the mediating factors of anxiety, depression, fatigue, sleep 
disturbance and pain interference. Participants in this study provided self-reports about 
their feelings of depression, anxiety, fatigue, and how well they sleep, in addition to how 
pain interferes in their ability to participate in everyday activities. The chemotherapy + 
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radiotherapy group’s mean anxiety scores were one standard deviation higher than the 
average US population for the entire six month time follow up period. Anxiety has been 
associated with self-reported cognitive problems for individuals treated for breast cancer 
(Biglia et al., 2011; Jansen et al., 2011). In designing this study, evidence relating to 
fear of reoccurrence, which is most likely tied into levels of anxiety, in breast cancer 
survivors was not examined. With the high levels of anxiety reported by participants and 
evidence showing a correlation of anxiety with decreases in self-reported cognition, 
exploration of the impact of fear of reoccurrence on participation in occupations is 
warranted. In the clinical setting, occupational therapists can provide interventions to 
assist clients with coping and compensating for their anxiety.  
 Mean t-scores for reports of depression did not change significantly during the 
study for either group and were above the standardized score of 50. Depression has 
been associated with an increase in self-report cognitive problems in several studies 
(Bender et al., 2009; Biglia et al., 2011; Jansen et al., 2011). Higher levels of depression 
were also associated with higher levels of fatigue (Jansen et al., 2011). Positive 
correlations between depression and fatigue were present for both groups in this study 
(Refer to Tables 9 & 10).  
 Fatigue scores dropped significantly in the chemotherapy + radiotherapy group 
during the six month period after treatment. The mean fatigue T-score for this group 
immediately after treatment was 62.28 dropping to 61.58 at six months, over 1SD 
greater than average over the entire study period. Fatigue scores were lower in the 
chemotherapy only group than the chemotherapy + radiotherapy group and did not 
significantly change over the six month follow up. The higher rates of fatigue in the 
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chemotherapy + radiotherapy group may be the result of the cumulative effects on the 
body from the treatments. In a recent study by Kishan et al. (2016) breast cancer 
patients reported increasing fatigue over the course of treatment, interestingly one of 
the predictors for higher level fatigue was younger age (>45). The majority of 
participants in this study were also younger. Fatigue is commonly associated with 
tiredness. The quality of sleep also impacts tiredness. In this study participants reported 
sleep disturbance levels above average, and the chemotherapy + radiotherapy group 
reported an increase in sleep disturbance further out from treatment. Anxiety, 
depression, fatigue, pain and sleep disturbance appear to be interrelated and it is 
extremely difficult to tease out the influence of each on cognition and functional 
performance. The small sample size limited the ability to perform post hoc analysis to 
explore trends in the relationship of these mediating factors to changes in cognition and 
functional performance.  
Limitations 
This was a small study with limited generalizability. The recruitment goal was for 
92 participants (46 per group) with the expectation of a 30% attrition rate. Recruitment 
for this study took place over a period of 10 months and only 16 participants met 
eligibility requirements and participated. Over the six month time period for follow up the 
attrition rate was approximately 50%. Follow ups during this study consisted of email 
communications.  
The small sample size and high attrition rate resulted in a need to alter the data 
analysis plan. The planned analysis with RM ANOVA and RM ANCOVA were replaced 
with linear mixed-effects models. Linear mixed-effects modeling allow for analyzing 
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repeated measures at the independent level, can be used when independence is 
violated and can use all data points, even if the individual did not complete the time 
series (Tabachnik & Fidell, 2007). The small sample size eliminated the ability to control 
for covariates such as age, menopause status, hypothyroid, and surgery effects, as well 
as performing post-hoc analysis.  
The study does not have a non-disease control group and did not have a pure 
disease control group of radiotherapy only. Therefore, no inference can be made 
regarding the impact of radiotherapy alone. The results of this study are not 
representative of the general breast cancer population and cannot be compared to the 
general population. Participants in this study self-selected, therefore self-selection bias 
is a concern. There is potential that some individuals did not participate because they 
predetermined they would not qualify.  
There is a tendency for breast cancer studies to have samples of middle class, 
white women. Fifteen out of the sixteen participants indicated they were white. 
According to the Institute of Medicine (IOM, 2010) only 3-5% of individuals diagnosed 
with cancer enroll in clinical trials. Through a systematic review covering 304 peer-
reviewed publications from 2001-2010, over 80% of the participants were white 
(Kwiatkowski, Coe, Bailar & Swanson, 2013).  
 Individuals with diverse backgrounds did not volunteer to participate in this 
study. Recruitment in the city of Harrisburg and Baltimore, as well as through a national 
organization did not result in an increase of diversity in the sample. This study 
attempted to address the bias of recruiting through social media by also recruiting 
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through oncology clinics and providing non-Internet users an alternative to participate 
with paper surveys. No requests for paper surveys were received.  
This study did not directly measure cognition through standardized, objective 
neurological testing. Additionally, functional performance was not measured on a 
standardized observational scale. The study relied entirely on self-report measures 
which may be impacted by recall bias, social desirability and errors in self-observation 
(National Collaborating Centre for Primary Care). Additionally, no conclusions about the 
causality of cognitive and functional changes may be drawn due to the lack of a pre-
treatment cognitive assessment. The optimal design would include pre-surgical 
cognitive assessment and pre-chemotherapy assessment with follow-ups (Wefel et al., 
2011). 
 Implications for Occupational Therapy 
 Occupational therapists have a strong tradition in the provision of cognitive 
rehabilitation services for developmental, traumatic, psychological and 
neurodegenerative conditions. An assumption is made that these skills will carry over to 
the cancer population and to some extent they do. However, occupational therapists 
must understand not only the etiology of the cognitive impairments but also the 
manifestations in the performance of occupations. This study is a beginning point for 
understanding some of the cognitive and functional performance difficulties that may 
occur after treatment for breast cancer. This study brings to light the complexity of 
PBBCI. Higher levels of fatigue, depression and anxiety were all highly correlated with 
lower levels of cognitive function, physical function and participation in social roles.  
 
 
85 
 
In the clinic, occupational therapist are responsible for assessing occupational 
performance.  Many individuals with breast cancer receive occupational referrals as a 
result of lymphedema. Occupational therapists need to look beyond the physical 
performance and remediation of lymphedema symptoms and screen for changes in 
cognition, as well as the presence of anxiety, depression and fatigue. These areas can 
quickly be screened through self-report with the PROMIS® scales.   
The top-down approach of occupational therapy views the client in a holistic 
manner and provides treatment with a broad based focus on the performance of 
personally meaningful activities.  Occupational therapists can assist individuals in the 
period following the conclusion of chemotherapy and radiotherapy treatment through the 
instruction and implementation of energy conservation, pain management and 
relaxation techniques, mindfulness training, developing compensatory strategies to 
cope with memory changes and cognitive behavioral therapy. Home based and 
technology based delivery of occupational therapy and cognitive behavioral therapy are 
beginning to emerge with successful outcomes (Cheng, Lim, Koh, & Tam, 2017; 
Ferguson et al., 2016; Lyons, Erickson & Hegel, 2012; Morean, O’Dwyer, & Cherney, 
2015). Additionally, group of researchers in Spain are currently recruiting for a 
randomized trial examining the use of occupational therapy for supportive care using a 
m-health approach (Lozano-Lozano et al., 2016).  
Breast cancer survivors may be referred to occupational therapy for only 
lymphedema treatment. It is the occupational therapists responsibility to thoroughly 
assess occupational performance and to look at the impact changes in cognition, 
anxiety, depression and fatigue may be having on their participation. The PROMIS® 
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instruments offer a quick, standardized way to assess and measure change in these 
factors.  Additionally, they offer norms for easy comparison.  The items on the 
PROMIS® scales provide insight into areas that should be evaluated in greater depth.  
 Recently the American Occupational Therapy Association began promoting the 
role of occupational therapy in oncology rehabilitation. Again this is primarily based in 
the assumption that assessment and intervention will transfer from other areas of 
practice. There is a paucity of occupational therapy specific research addressing 
cognitive impairment within cancer rehabilitation. Recently published research reviews 
published in the American Journal of Occupational Therapy (AJOT) are based on the 
analysis of evidence from other disciplines (Baxter, Newman, Longpré, & Polo, 2017; 
Hunter, Gibson, Arbesman & D’Amico, 2017a; Hunter, Gibson, Arbesman & D’Amico, 
2017b). This study is a beginning point to better understanding the impact of PBCCI on 
functional performance. Furthermore, no occupational therapy studies were located in a 
recent search of currently funded NIH projects related to intervention for cognitive 
impairment related to cancer.  
The PROMIS® instruments used in this study were designed for both research 
and clinical use and serve as a convenient method for gathering information on multiple 
factors related to cognition and cancer. Occupational therapists can use these 
instruments to screen clients and to measure changes over the course of treatment. In 
fact, PROMIS® instruments are readily available in some of the major electronic 
medical record systems.  
 In this sample, the ability to participate in social roles and activities was lower 
than the average for a chronic illness enriched general US population. This is an area in 
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which occupational therapists can provide intervention to improve participation. The 
theoretical foundation for this study, the Model of Human Occupation, is focused on 
understanding the performance of occupations by taking into account volition, habits 
and performance capacity. From this study it may be hypothesized that depression and 
anxiety may impact an individual’s volition. Performance capacity may be impacted by 
cognitive and physical changes resulting from the disease process and associated 
treatment. 
 Additionally, it is vital that occupational therapists work collaboratively with the 
oncology team. The Conceptual Model of Chemotherapy-Related Changes in Cognitive 
Function developed in the nursing field provides a framework for occupational therapists 
to understand the complexity of factors that contribute to PBCCI. The model provides a 
basic definition of functional performance. Occupational therapy models, such as 
MOHO, provide a way to extend the model to reflect the functional trajectory of the 
client with cancer.  
Despite the attention that PBCCI is receiving in the research community, this 
information does not appear to be changing clinical intervention for survivors. In a study 
of over 2,000 breast cancer survivors in the US, 60% of the sample self-reported 
cognitive problems (Buchanan, et al., 2015). Of these, 37% discussed these concerns 
with their medical provide and a mere 15% of these individuals reported receiving any 
type of treatment (Buchanan, et al., 2015). Survivors are not being referred to services 
such as occupational therapy that address changes they are noticing in their cognition 
and ability to perform everyday activities. Occupational therapy provides a unique and 
holistic approach to the treatment of cognitive impairment with a focus on participation 
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in meaningful occupations. As a profession, occupational therapists must advocate for 
our role in the cognitive rehabilitation of cancer survivors.  
Recommendations for Future Research 
 This study scratched the surface in understanding the connection of self-reported 
cognitive impairment and its relationship to changes in functional performance. Further 
research needs to better describe the impact of cancer treatment, not only as it 
concerns changes in cognition but as a whole, on the participation in daily meaningful 
occupations. The design of this study can be improved upon to provide one approach to 
this end. First, a better design would be to enroll participants prior to beginning 
treatment to provide a baseline for functional performance and cognition. The study 
might also include additional comparison groups: a chemotherapy only group, a 
chemotherapy and radiotherapy group, a radiotherapy only group and a hormone 
therapy only group. The inclusion of standardized neurological assessments may also 
strengthen the design. Objective neurological assessments would provide a way to 
pinpoint specific deficit areas. For example, the Rivermead Behavioral Memory 
Assessment would provide better information about the domains of memory that are 
impaired and the extent of the impairment. Likewise, the Test of Everyday Attention can 
provide more detail about deficits in attention. The sample size should be increased to 
adequately power the study. Special attention should be paid to recruitment procedures 
and methods for follow-up to limit attrition. This study followed participants for 6 months. 
This is a very short period. A greater length of follow up is needed to understand the 
long term impacts of cancer diagnosis and treatment on cognition and function.  
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 This study depended on self-report measures. Other studies attempting to 
measure cognition related to breast cancer treatment heavily relied on standardized 
neuropsychological testing (Ahles, Root & Ryan, 2012). Standard neuropsychological 
testing is heavily decontextualized from the demands of everyday living with testing 
environments that remove all distractors (Nelson & Suls, 2013; Hutchinson, et al. 2011). 
This poses a problem, as the impact of PBCCI on activities and participation has not 
been measured with standardized, valid and reliable assessments. Research utilizing 
an ecological approach to the evaluation of cognition is needed. Ecological 
assessments are designed to measure cognitive function within the demands of real life 
living. Occupational therapists often use ecological approaches to evaluation and are 
well suited to perform research that would examine the utility of an ecological approach 
in assessing cognitive impairments associated with cancer treatment.  
Additionally, well designed studies are needed to examine the efficacy of 
occupational intervention for cognitive impairment. Studies are needed to compare 
occupational intervention to other interventions and also in combination with other 
treatments, in order to provide cancer survivors with the best options.  
This study excluded participants with metastatic breast cancer and several 
women expressed disappointment about not being able to participate. They too, face 
cognitive impairments that impact their ability to do the things they want to do. Research 
is needed in understanding the unique changes in cognition and activities and 
participation of this population. As current treatments are extending the life 
expectancies of individuals living with Stage VI cancer, these people want to continue 
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doing things they like to do. Occupational therapy has the potential to provide 
interventions that will improve the quality of life for these individuals.  
Conclusion 
 When people complete cancer treatment they are forced into a life transition. 
This follows a period in which medical appointments, surgeries, invasive radiation or 
chemotherapy treatments and recovery periods have dominated their days. The big 
question for survivors is “What’s next?” or “How do I get back to normal?” There are no 
guides for this transition and little support is provided from the medical establishment. 
Survivors may go from one day to the next wondering when they will feel like 
themselves again. As survivors transition back into fuller levels of participation, the after 
effects of treatment become more visible. Perhaps when the car keys were misplaced 
before the cancer diagnosis it was viewed as the temporary absent-mindedness of a 
busy person. After cancer such a miscue may be viewed as a symptom of the disease 
or a result of invasive treatment and put in a category with forgetting names and 
appointments or having trouble doing calculations. It is difficult to determine if self-
reports are the result of changes in brain function or if they are the result of heightened 
awareness and a desire to live as one recalled living before cancer. In either scenario, 
occupational therapy intervention can facilitate increased participation and engagement 
in occupations for cancer survivors.  
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111 
 
 
 
TITLE: The Impact of Chemotherapy and Radiotherapy for Breast Cancer on 
Cognition and Functional Performance: A Comparative Analysis of Survey Data 
taken at Three Time Points Post-Treatment 
 
VCU IRB PROTOCOL NUMBER: HM20006120 
INVESTIGATOR: Lynwood Gentry, PhD 
 
If any information contained in this consent form is not clear or you have any questions, please 
contact the study staff, by phone or email using the contact information at the end of this 
document, to explain any information that you do not fully understand. You may take time to 
think about or discuss this consent form with family or friends before making your decision. 
When you are ready to decide return to this website to continue. 
 
PURPOSE OF THE STUDY 
The purpose of this research study is to find out how cognition and the ability to do everyday 
activities changes in the 6 months after the completion of treatment for breast cancer. 
You are being asked to participate in this study because you are nearing the end of 
chemotherapy or radiotherapy for breast cancer 
 
DESCRIPTION OF THE STUDY AND YOUR INVOLVEMENT 
If you decide to be in this research study, you will be asked to indicate that you consent to 
participate in the research by checking a box after you have had all your questions answered 
and understand what you will need to do. 
 
Once you submit your consent form, you will be directed to an eligibility questionnaire. This 
questionnaire will ask you questions about your breast cancer diagnosis and treatment, and 
your medical history. If you are eligible to continue in the study you will be redirected to the 
study surveys about your daily activities and cognitive function. 
 
If you are eligible for this study you will be asked to complete online surveys three different 
times. The first time you complete the surveys will be about two weeks after you complete 
either chemotherapy or radiation. Then you will complete the same surveys 3 and 6 months 
later. You will receive an email or text reminders to keep on schedule. The survey will ask you 
demographic and medical history questions, as well as questions about your general health, 
activities that you are able to do and how well you feel you do these activities, your attention 
and memory, and concerns that you have 
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such as feeling nervous or fearful. The surveys will take 15-30 minutes to complete. During the 
first survey you will also be asked to refer a caregiver or someone close to you that you see on 
a regular basis, and is over 18 years of age, to participate by providing an email address or 
phone number (text or voice) for that person. The caregiver will be asked similar questions 
about how they observe your ability to do daily activities. If you do not have a caregiver to 
refer or do not want to refer a caregiver you will still be able to participate in the study. 
 
RISKS AND DISCOMFORTS 
Sometimes thinking about these subjects causes people to become upset. Several questions will 
ask about feeling depressed or anxious. You do not have answer any questions that you do not 
want to and you may leave the study at any time. If you become upset, you may contact the 
study staff with the information provided at the end of this document and you will be given the 
name of a support group to contact so you can get help in dealing with these issues. 
 
 
USE AND DISCLOSURE OF PROTECTED HEALTH INFORMATION 
 
Authority to Request Protected Health Information 
The following people and/or groups may request my Protected Health Information: 
• Principal Investigator and Research Staff 
• Institutional Review Boards 
• Government/Health Agencies 
 
Authority to Release Protected Health Information 
The VCU Health System (VCUHS) may release the information identified in this authorization 
from my medical records and provide this information to: 
• Health Care Providers at the VCUHS • Principal Investigator and Research Staff 
• Study Sponsor • Research Collaborators 
• Data Coordinators • Institutional Review Boards 
• Data Safety Monitoring Boards • Government/Health Agencies 
• Others as Required by Law 
 
Once your health information has been disclosed to anyone outside of this study, the 
information may no longer be protected under this authorization. 
Type of Information that may be Released 
The following types of information may be used for the conduct of this research: 
Complete health record Diagnosis & treatment 
codes 
Discharge summary 
  
  
   
 
 Consultation reports  Progress notes 
Laboratory test results  X-ray reports  X-ray films / 
i   
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Photographs, videotapes Complete billing record Itemized bill 
Information about drug or alcohol abuse Information about Hepatitis B or C tests 
Information about psychiatric care Information about sexually transmitted 
diseases 
Other (specify): 
 
 
Expiration of This Authorization 
 
This authorization will expire when the research study is closed, or there is no 
need to review, analyze and consider the data generated by the research project, 
whichever is later. 
This research study involves the use of a Data or Tissue Repository (bank) and 
will never expire. 
Other (specify): 
 
Right to Revoke Authorization and Re-disclosure 
You may change your mind and revoke (take back) the right to use your protected health 
information at any time. Even if you revoke this Authorization, the researchers may still use or 
disclose health information they have already collected about you for this study. If you revoke 
this Authorization you may no longer be allowed to participate in the research study. To 
revoke this Authorization, you may write, email or text message the Principal Investigator with 
your request. 
 
BENEFITS TO YOU AND OTHERS 
You may not get any direct benefit from this study, but, the information we learn from people 
in this study may help us design treatments that will help individuals transition out of 
treatment and back to full living. 
 
COSTS 
There are no costs for participating in this study other than the time you will spend filling out 
questionnaires. 
 
PAYMENT FOR PARTICIPATION 
If you are eligible to participate in this study, you will receive an electronic $10.00 gift certificate 
to Amazon.com or Starbucks, at an email address you provide, once you have completed the first 
survey. You will also have the option to donate $10 to the Young Survival Coalition if you do not 
want a gift certificate. 
 
ALTERNATIVES 
If you would like to complete this study with paper surveys please contact the primary 
investigator, Ann Marie Potter, listed below. You may call, email or text message. You will be 
asked to provide a mailing address where you would like to receive the consent form and 
surveys. You will first receive the consent form and eligibility survey. Once 
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your completed consent forms are received and you are determined eligible, the study surveys 
will arrive by mail. This will be about 2 weeks after you complete radiation or chemotherapy, 
and again 3 and 6 months later. 
 
CONFIDENTIALITY 
Potentially identifiable information about you will consist of your name, birth date, email 
address, home address, breast cancer diagnosis, and survey data. Data is being collected only 
for research purposes. 
 
Your data will be identified by a computer assigned ID numbers, not names, and stored 
separately from research data in a password protected file. All personal identifying information 
will be kept in separate password protected files and these files will be deleted in 5 years. 
Access to all data will be limited to study personnel. If you are not eligible for the study your 
data will be deleted prior to the data analysis phase of the project. 
 
We will not tell anyone the answers you give us; however, information from the study may 
be looked at or copied for research or legal purposes by Virginia Commonwealth University. 
Personal information about you might be shared with or copied by authorized officials of the 
Department of Health and Human Services or other federal regulatory bodies. 
 
What we find from this study may be presented at meetings or published in papers, but your 
name will not ever be used in these presentations or papers. 
 
VOLUNTARY PARTICIPATION AND WITHDRAWAL 
You do not have to participate in this study. Your decision not to take part will involve no 
penalty or loss of benefits to which you are otherwise entitled. If you choose to participate, 
you may stop at any time without any penalty. Your decision to withdraw will involve no 
penalty or loss of benefits to which you are otherwise entitled. You may also choose not to 
answer particular questions that are asked in the study. 
 
Your participation in this study may be stopped at any time by the study staff without your 
consent. The reasons might include: 
• the study staff thinks it necessary for your health or safety; 
• you have not followed study instructions; 
• administrative reasons require your withdrawal. 
 
 
QUESTIONS 
If you have any questions, complaints, or concerns about your participation in this research, 
contact: 
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Ann Marie Potter, MA, OTR/L - Doctoral Candidate, Researcher Email: pottera2@vcu.edu 
Phone/Text: 717-298-7005 Mail: Elizabethtown College, 
One Alpha Drive, Occupational Therapy Department, 
Elizabethtown, PA 17022 
and/or 
Tony Gentry, PhD. – Advisor Email: logentry@vcu.edu Phone: 804-828-3397 
Mail: Department of Occupational Therapy 730 East Broad Street 
P.O. Box 980008 
Richmond, Virginia 23298-0008 
 
The researcher/study staff named above is the best person(s) to call for questions about your 
participation in this study. 
 
If you have any general questions about your rights as a participant in this or any other 
research, you may contact: 
 
Office of Research 
Virginia Commonwealth University 800 East Leigh 
Street, Suite 3000 
P.O. Box 980568 Richmond, VA 23298 
Telephone: (804) 827-2157 
 
Contact this number to ask general questions, to obtain information or offer input, and to 
express concerns or complaints about research. You may also call this number if you cannot 
reach the research team or if you wish to talk with someone else. General information about 
participation in research studies can also be found at 
http://www.research.vcu.edu/irb/volunteers.htm. 
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PROMIS® Instruments 
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Ann Marie Potter [ampotter.otr@gmail.com] 
 
Actions  
To: 
 Potter, Ann M  
  
Sunday, July 05, 2015 3:58 PM 
---------- Forwarded message ---------- 
From: Stacie Jeter <e> 
Date: Thu, May 21, 2015 at 4:33 PM 
Subject: RE: Follow up from Thursday 
To: Ann Marie Potter <ampotter.otr@gmail.com> 
 
Ann Marie, I wanted to follow-up with you as I was finally able to connect with one of the folks 
in our IRB. If not to have the study approved by our IRB here at Hopkins, we are not allowed to 
post information in our clinic about the study or include the study in a list of “our” clinical trials 
on our websites/handouts; however, our medical oncologists could hand a flier to potentially 
eligible patients when they see them in clinic that gives them info about the study and invites 
them to contact you directly. I think that this should still work/help – and save the regulatory 
effort. Good news!  Stacie 
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 Hi Ann Marie! 
  
I reviewed the submission for your research project “The Relationship between Post Breast 
Cancer Cognitive Impairment and Function.”  YSC would be glad to post about your study on 
social media to aid in your recruitment efforts. Since it looks like participants must be in the 
Pennsylvania/Baltimore area, I am thinking that our NorthEast Regional Facebook page would 
be the best place to advertise, but we can also post on the national YSC Facebook page too and 
Twitter. When your study is IRB approved and you’re ready to recruit patients, please send me 
your proposed text for posting. 
  
I hope you are well. Are you going to BCY2? 
 
Best, 
  
Michelle 
  
Michelle Esser 
Program Manager, Research and Advocacy • Survivor 
YOUNG SURVIVAL COALITION 
Young women facing breast cancer together. 
Work days:  Monday through Thursday 
c 215.588.5572 I  youngsurvival.org 
Like us on Facebook and Follow us on Twitter and Instagram 
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List of support groups contacted 
 
Pink Ribbon Friends 
Cancer Caring Center 
Pink Ribbon Girls 
The Small Group Ministry for Breast Cancer Support 
P.I.N.K Partners York 
Celebrating Hope in Cancer Survivors (CHICS) 
ABC Breast Cancer Support Group (YWCA of Carlisle) 
Hanover Area Breast Cancer Support Group 
ENCORE (YWCA of Allentown) Breast Cancer Recovery Program 
Cancer Support Community of the Greater Lehigh Valley 
Breast Cancer Support Services of Berks 
Breast Friends of PA Breakfast Club 
The Cancer Support of Greater Philadelphia 
The Healing Foundation of Bucks County 
Linked By Pink (Erie) 
Looking Ahead Breast Cancer Support Group (Meadville) 
Warren County Women's Cancer Support Group 
Mercer County Breast Cancer Support Group 
Our Clubhouse (Pittsburgh) 
Pink Steel Dragon 
Butler Breast and Women's Cancer Support Group 
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Confidence Intervals Tables 
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Table F1 
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among T-
Score Changes over the Six Months Post Treatment 
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Table F1 continued 
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among T-
Score Changes over the Six Months Post Treatment 
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Table F2 
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among T-
Score Changes over the Six Months Post Treatment 
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Table F2 continued 
Chemotherapy + Radiation group 95% Confidence Intervals for Correlations among T-
Score Changes over the Six Months Post Treatment 
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1989. She received a Master of Arts in Occupational Therapy from University of 
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